




Translating Knowledge of Autism Spectrum




Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Garcia, Rebecca A., "Translating Knowledge of Autism Spectrum Disorders to Action Through Tool Development and Exploration"
(2014). All Dissertations. 2405.
https://tigerprints.clemson.edu/all_dissertations/2405
TRANSLATING KNOWLEDGE OF AUTISM SPECTRUM DISORDERS 
 TO ACTION THROUGH DISCOVERY AND EXPLORATION 
A Thesis  
Presented to  
the Graduate School of 
Clemson University 
In Partial Fulfillment  
of the Requirements for the Degree 
Doctor of Philosophy 
Healthcare Genetics 
by 
Rebecca Ashmore Garcia 
August 2014 
Accepted by: 
Dr. Julia Eggert, Committee Chair 
Dr. Margaret A. Wetsel 
Dr. D. Matthew Boyer 
Dr. Alex Feltus 
Dr. Brent Satterfield 
 ii 
ABSTRACT 
Translational processes are needed to move research development, methods, and 
techniques into clinical application. The knowledge to action framework organizes this 
bench to bedside process through three phases including: research, translation, and 
institutionalization without being specific to one disease or condition. The overall goal of 
this research is to bridge gaps in the translational process from assay development to 
disease detection through a mixed methods approach. A literature review identifies gaps 
associated with intestinal permeability and autism spectrum disorders. Mining social 
media related to autism and GI symptoms captures self-reported or observed data, 
identifies patterns and themes within the data, and works to translate that knowledge into 
healthcare applications. Development of novel tests can then examine relationships 
between zonulin levels, haptoglobin genotype, and autism spectrum disorders, and 
propose a paradigm shift in the use of proteomics and genomic diagnostic testing from 
clinical diagnosis to pre-symptomatic testing. Although results from this study do not 
find statistically significant relationships between zonulin and autism spectrum disorders, 
they do suggest clinical significance and the need to conduct larger studies. The 
discovery presents a novel approach for measuring intestinal permeability. Qualitative 
and quantitative methods collaboratively point toward implementation of molecular and 
data mining techniques in the development and evaluation of early diagnostic tests and 
interventions. Equally, the two methods working together drive the field forward in 
design and development to strengthen the outcomes.  
Keywords: autism, zonulin, Radian6, haptoglobin, social media 
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ABBREVIATIONS 
ASD Autism Spectrum Disorder 
ALI Acute lung injury 
ALT Alanine aminotransferase 
ARDS Acute respiratory distress syndrome 
AST Aspartate aminotransferase 
BBB Blood brain barrier 
CARS Childhood Autism Rating Scale 
CDC Centers for Disease Control and Prevention 
CF Complement fixation 
c-kit V-KIT Hardy-Zuckerman 4 feline sarcoma viral oncogene
ctx Cholera toxin
CXCR3 Chemokine (C-X-C motif) receptor 3
DAG Diacylglycerol
DNA Deoxyribonucleic acid
DSM Diagnostic and Statistical Manual of Mental Disorders
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assays
ER Endoplasmic reticulum
GAPS Gut and psychology syndrome
GARS Gilliam Autism Rating Scale
gDNA Genomic deoxyribonucleic acid
GI Gastrointestinal
GLP-2 Glucagon-like peptide 2








IRB Internal Review Board
K2A Knowledge to Action Framework
LM Lactose mannitol
M Mean
mRNA Messenger ribonucleic acid
mi-RNA micro-ribonucleic acid
MRC British Medical Research Council




NP Nurse practitioner 
NS1 Non-structural protein 1 antibody 
PAR2 Protease activated receptor 2 
PCR Polymerase chain reaction 
PPI-3 Inositol 1,4,5-tris-phosphate 
Pre-HP2 Pre-haptoglobin 2 or zonulin 
PRNT Plaque reduction and neutralization tests 
RBMECs Rat brain microvascular endothelial cells 
RNA Ribonucleic acid 
SD Standard Deviation 
SPSS Statistical package for the social sciences 
STAT3 Signal transducer and activator of transcription 3 
TJ Tight junctions 
US United States 
WHO World Health Organization 
ZOT Zonulin occludins toxin 
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Early diagnostics make up the engine core that thrusts public and private research 
through the translational process after discovery and development into clinical 
application. Qualitative and quantitative methods are equally important in driving 
research design toward conclusive experiences and evidence of disease states to 
strengthen research outcomes.  
Exposure to bacteria can occur at any time from conception to adulthood. Even 
though childhood exposures may not be pathogenic, they may contribute to activation of 
disease pathways. For example, zonulin is a protein that regulates the epithelial 
permeability allowing macromolecules to pass into the blood stream (Tripathi et al., 
2009; Wang, Uzzau, Goldblum, & Fasano, 2000). Normally this process assists in 
epithelial barrier protection from invading pathogens; however, the constitutive action of 
zonulin increasing epithelial permeability can also result in molecules passing through 
the barrier to initiate immune response and disease development (Drago et al., 2006; 
Duerksen, Wilhelm-Boyles, Veitch, Kryszak, & Parry, 2010). Studies have identified 
zonulin’s specific roles in intestinal and blood brain barrier permeability (Cipriani et al., 
2011; Diaz-Coranguez et al., 2013; Duerksen et al., 2010; Fasano et al., 2000; Lu et al., 
2000; Wang et al., 2000). The type of permeability suggests zonulin may play a role in 
the pathological development of autism spectrum disorder (ASD) and related symptoms.  
ASD affects 1 in 68 children in the United States (U.S.) with no known cause or 
diagnostic test (Centers for Disease Control and Prevention [CDC], 2014). Interventions 
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for autism typically involve multiple levels of trial and error using medication, 
supplements, and an array of therapies with an annual expected lifetime cost of care at 
$2.4 million per individual (Buescher, Cidav, Knapp, & Mandell, 2014).  
Using the Center for Disease Control and Prevention’s (CDC) National Center for 
Chronic Disease Prevention and Health Promotion (NCCDPHP) ‘Knowledge to Action’ 
framework, this dissertation participates in discovery through practice (Wilson et al., 
2011). The overall goal of this dissertation is to determine if it is possible to bridge gaps 
in the translational process from assay development to disease detection through a mixed 
methods approach.  
Knowledge to Action Framework 
The Knowledge to Action (K2A) framework used for this research project was 
created by the CDC to organize the processes from bench to bedside through three phases 
including research, translation, and institutionalization without being specific to one 












Figure 1.1  
NCCDPHP Knowledge to Action Framework for Public Health 
 
Figure 1.1 NCCDPHP Knowledge to Action Framework for Public Health. The figure 
illustrates the three phases of the NCCDPHP K2A framework used with permission from 
Wilson et al., 2011.  
 
In this framework, each phase is made up of multiple components. For the purpose of this 
dissertation, the definitions used by the CDC’s NCCDPHP K2A framework are 
embraced. The research phases reflected in the subsequent chapters are the focus of this 
dissertation project (Wilson et al., 2011).  
The term ‘research’ refers to the first phase within the K2A framework and 
includes discovery, efficacy, effectiveness, and research supporting structures (Wilson et 
al., 2011). These guide the process of this dissertation research. Discovery encompasses 
epidemiological, behavioral, and biomedical studies (Wilson & Fridinger, 2008). 
Discovery is also comprised of initial ideas and thoughts that lead from synthesis of 
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literature to development of a research plan. Discovery entails investigations of literature, 
data, observations, and experiences. The discovery phase explores the literature to 
establish a background and path moving forward. Discovery studies provide proof-of-
concept in order to acquire a larger research support network of organizations, scientists, 
sample sizes, and funding. Efficacy and effectiveness intertwines with discovery to 
explore where present interventions and testing fails or excels (Wilson & Fridinger, 
2008). Efficacy refers to formative research, where attitudes, beliefs, and experiences can 
be explored and incorporated into development of diagnostic tests and interventions 
(Wilson & Fridinger, 2008). Efficacy allows the voice of the stakeholders to be 
incorporated into the research model (Wilson & Fridinger, 2008). Results from these 
initial experiments provide evidence to gather support from multiple disciplines and 
investors to launch a full investigation that will either lead to the decision to translate or 
continue with more discovery studies.  
The K2A framework recognizes the need to incorporate all disciplines in the 
translational process in order to put knowledge into action (Wilson et al., 2011). Part of 
this translation includes measuring the gap between what is found in guidelines, the 
literature, and to practice (Kitson & Straus, 2010). Chapter II provides a review of the 
literature surrounding epithelial permeability, zonulin, and ASD. The review identifies a 
gap in the literature in studies associating intestinal permeability with ASD and serum 
zonulin levels in ASD individuals (D’Eufemia et al., 1996; De Magistris et al., 2010). 
When gaps provide useful and relevant knowledge, exploring these gaps through 
templates and tools can identify needs, gather resources, evaluate knowledge, discern 
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good from bad, and make information available to others (Turnbull et al., 2010). Social 
media data mining provides this capability when focused on a specific disease or list of 
symptoms. Chapter III is a discovery and efficacy study that looks for patterns among 
people with ASD and gastrointestinal (GI) symptoms in social media data. The social 
media research is part of discovery through collection of observations and experiences 
and it is an efficacy study through its compilation of attitudes and beliefs of the 
participants. Chapter IV follows with a discovery and efficacy study that measures 
zonulin levels and haptoglobin genotype of ASD individuals, newborns, and healthy 
controls to determine if zonulin can effectively detect the presence of ASD as an early 
diagnostic test. Effectiveness research expands the optimal discovery and efficacy studies 
to the translational phase through clinical trials and application (Wilson & Fridinger, 
2008).   
The clinical trials process follows a set of guidelines to ensure that a drug, 
medical device, or therapy works efficiently and effectively without harming patients. 
Each country has its own regulations that must be met before a product can pass this 
stage and be sold to consumers. Clinical trials focus on reproducibility of efficacy and 
effectiveness studies, and add double blind studies to eliminate possible researcher bias to 
the outcome (Hróbjartsson et al., 2013). Repetition is necessary because the response in 
humans may be different from those recorded from in vitro studies. Communication 
between stakeholders is pertinent at this point to identify the needs and risks of 
implementing scientific research into clinical practice (Droms, Ferguson, & Giuliano, 
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2014). Stakeholders might include parents, caregivers, individuals with ASD, insurance 
companies, clinicians, organizations, government agencies, or education sources.   
Once the first phase of research is ended, the second phase of translation begins. 
The K2A framework delineates translation as: decisions to translate, knowledge into 
products, dissemination, engagement, decisions to adopt, practice, and translation 
supporting structures (Wilson & Fridinger, 2008; Wilson et al., 2011). Translation is the 
process by which an application is moved from the development phase into use in a 
clinical setting. The process may include extensive validation procedures that confirm the 
specificity and sensitivity of the test, as well as correlation studies with samples that have 
been previously tested by a validated testing method. In many cases there is movement 
between phases based on need to revisit the experimental processes related to the need to 
refine and improve methods as a result of unexpected consequences of implementation, 
advances in technology, environmental changes, or knowledge of genetic factors.  
Research Phase of Zonulin Testing 
The most common type of research in healthcare is quantitative research; 
however, qualitative research is also important in understanding the patient experience, 
assessment, diagnosis, and treatment. The early physicians, such as Hippocrates (460 
B.C. -377B.C.), used observations and taste to determine disease states with a record of 
their findings in journals (Medvei, 1993). Visual observations continued to be the 
primary source of health assessment for diabetes until the first quantitative test was 
developed in 1841 by Carl Trommer; followed by the more well-known urine sugar test 
 7 
 
developed by Hermann Fehling in 1848 (Medvei, 1993). As technology advanced and 
more tests were developed, quantitative research became embedded in healthcare.  
Today, researchers question whether one type of research is enough to provide 
quality of care. Stuart and Wiles’ (1997) comparisons of questionnaires and interviews 
suggest that use of only one type of research does not assess the complete understanding 
of information, and it provides misleading information when used alone. The lack of 
reproducibility between questionnaire and interview responses was significant (p<0.008), 
indicating a lack of information about patient needs, beliefs, and experiences necessary to 
facilitate self-management (Stuart & Wiles, 1997). Zhang and Creswell (2013) identify 
outcomes of mixed methods in convergence, complementarity, development, initiation, 
and expansion; whereas, the use of only quantitative methods fail to capture perspectives 
from broad, complex groups. Both quantitative and qualitative research is needed to 
develop and implement successful interventions and treatments. This dissertation uses 
both qualitative and quantitative research to provide a more complete view of the 
relationship between GI symptoms and ASD.  
 Quantitative and qualitative research looks at people and disease to identify a 
problem and develop a research plan to test a hypothesis. In the field of healthcare, 
stakeholders represent individuals and families affected by the same disease, those 
experiencing similar symptoms, those going through similar therapies, healthcare 
professionals, drugs, diseases, new technologies, or equipment. The stakeholders 
involved in this dissertation research include individuals with ASD, caregivers or family 
members, healthcare professionals, and private and public organizations. Each of these 
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stakeholders may be affected or represented in the data collected from social media 
outlets. The stakeholders are not always involved in the research groups, but they may be 
indirectly affected by the research outcomes. Differences can be seen in the methodology, 
data collection, and analysis of these groups. The term ‘quality’ has been recently defined 
in healthcare as “the degree to which policies, programs, services, and research for the 
population increase desired health outcomes and conditions in which the population can 
be healthy” (Honore et al., 2012, p.739). Table 1.1 provides a list of common and 
healthcare definitions for quality and quantity  
Table 1.1  
 






character  Accessibility and familiarity (Lee et al., 2013) 
capacity  Test results (Lee et al., 2013) 
vividness of hue Evidence- based practice (Lee et al., 2013) 
degree of 
excellence  
cost effectiveness and service delivery (Lee et al., 2013) 
Superiority   A management process, set of tools, and techniques used to meet 
healthcare needs (Riley et al., 2010) 




provides details of behavior, routines, needs, and personality 
characteristics (Madrigal & McClain, 2012) 
social status examines patterns and relationships in the data to develop and test 
hypotheses to generate theory or develop theory to explain data 
(Morse & Field, 1995) 
role Effectiveness, access and timeliness, capacity, safety, patient 
centeredness, and equity measurements (Committee on Quality of 
Health Care in America, Institute of Medicine, 2001) 
feature reaching a desired health outcome (Brilli et al., 2014) 
Quantity 
Amount, estimate, theory based, structured, systematic, planned, objective, logical, and 
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or number  dependent on scientific thought (Berger, 2013) 
Table 1.1 Quality and Quantity Definitions. The definitions for both terms above are 
taken from Berger, 2013; Brilli et al., 2014; Committee on Quality of Health Care in 
America, Institute of Medicine, 2001; Lee et al., 2013; Madrigal & McClain, 2012; 
Morse & Field, 1995; Riley et al., 2010.   
 
The combination of qualitative and quantitative measures increases the strength of 
the findings and moves science forward through the K2A framework to the translation 
phase. To begin the testing process, only quantitative research requires the formation of a 
research plan through the identification of a problem and development of a testable 
hypothesis. The strength of qualitative research can be found in description of the 
problem and understanding how the intervention or research plan will work. Models and 
diagrams can assist in conceptualization of the problem. These can be generated from 
qualitative or quantitative software programs. In qualitative research, the hypothesis may 
not be formed until data has been examined, at such point the hypothesis or research 
questions may be edited. Patterns and relationships in qualitative data can be used to 
develop and test hypotheses and to develop theories (Heyvaert, Maes, & Onghena, 2013; 
Morse & Field, 1995).  
Qualitative research is designed around a set of open ended research questions, so 
the researcher can capture the viewpoint and context of the data being collected. Context 
is important to qualitative research because it holds the meaning of the data. Questions 
may differ depending on the design type, but they focus on understanding a single 
concept, discussing the results, and incorporating new-understandings and ethical, 
appropriate use of tests (Creswell, Hanson, Clark Plano, & Morales, 2007; Fetters, Curry, 
& Creswell, 2013). Qualitative research has multiple design types such as narrative 
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research, case study, grounded theory, phenomenology, and action research (Glesne, 
2010). More than one design type can be used in an experiment or it can be mixed with 
quantitative methods (Fetters et al., 2013; Palinkas et al., 2013).  
Limitations and questions exist when exploring the use of mixed methods 
research (Palinkas et al., 2013). The complexity of the data makes it difficult to analyze. 
One example is that text and behaviors may have multiple meanings within the same 
population; even more intensified across cultures and countries. Many times the question 
arises “is the research beneficial; is it a worthwhile cause?” Bendassolli (2013) discusses 
problems of induction of qualitative research explaining that in many circumstances 
adequate information does not exist to formulate a theory and therefore nothing can be 
tested. In addition, excessive amounts of data can overwhelm the analytical process; 
therefore, researchers need to know how to manage and analyze large data sets.  
Automation has sought to resolve analysis problems of large data sets in multiple 
forms of research. Reliance on automation in qualitative data could lead to loss of context 
or meaning of the data; therefore, automation should be viewed as a tool to help the 
analyst interpret the data (Angus, Rintel, & Wiles, 2013).  Another limitation shared 
between qualitative and quantitative research is researcher bias. Berger (2013) explains 
that when a person believes something should be done, he/she becomes selective and 
neglects fully informative data. Berger (2013) associates the term quality with evaluation, 
judgment, and taste. In qualitative research, this is also seen in data collected due to a 
person’s motivation or personal interests in the research outcome.  
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Motivation and involvement by researchers and participants can also be beneficial 
in qualitative research (Barakat et al., 2013). Since qualitative research attempts to 
capture the context of the data, it can be very powerful and useful in describing the 
beliefs, desires, struggles, motivations, and responses to intervention of some groups 
(Nicolaidis et al., 2011). For example, individuals who are diagnosed with ASD often do 
not have a voice in research methodologies and designs.  The autistic community has 
been compared to voices of lesbian, gay, bisexual, transgendered, deaf individuals as they 
represent individuals with a unique phenotype that is not shared by the rest of their 
families (Nicolaidis et al., 2011). Qualitative research can capture the voices of these 
minority groups without losing their passion and motivation to identification as a number. 
By listening to the voices of those with ASD and their families, researchers can 
incorporate their concerns and ideas into interventions and technologies (Nicolaidis et al., 
2011; Rowe & Nevin, 2013).  
Ethically speaking the inclusion of all stakeholder points-of-view is vital in 
developing technologies and/or resources that are both utilitarian and non-maleficent. 
Although quantitative research is assuming more non-invasive methods of collection, it 
does not maintain individual autonomy. In order to protect the anonymity of human 
subjects, all forms of research removes the identity of a person. The representation of 
autonomy and preservation of context in qualitative research may ultimately be its demise 
in protecting individuals or organizations. For example, a simple search or publication of 
reported data or phrases may inadvertently identify an individual, group, or organization. 
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Much detail in protection of human subjects and de-identification of data must take place 
in the development of both research methods.  
The role of qualitative research in healthcare intervention is important and as a 
result guidelines and checklists have been created to provide a framework for 
development. In 2000, the British Medical Research Council (MRC) recognized that 
qualitative research could provide beneficial information for complex medical 
interventions (Medical Research Council, 2000). The MRC published guidelines in 2000 
that proposed using qualitative research to identify mechanisms and determine 
effectiveness of interventions. These guidelines were updated in 2008 to focus on 
qualitative properties that maintain context of information (Medical Research Council, 
2008). These guidelines help in development of a framework to approach qualitative 
research. Using these guidelines, this research incorporates them into the K2A 
framework.   
Exploring Social Media 
The research phase of this project is divided into two parts based on utilization of 
qualitative and quantitative methods to reach the overall goal of developing early 
diagnostic tests for ASD based on gastrointestinal symptoms. The qualitative portion of 
this research compares relationships between known physiological effects of zonulin and 
symptoms of ASD recorded through social media and phenotypic assessment. This study 
utilizes three months of public information to identify symptoms of ASD described 
through social media.  Radian6 software designed to assist with queries of social media 
was used to collect the data. The ASD social media data was analyzed to identify 
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symptoms unique to autism implicating epithelial permeability physiological pathways 
related to increased risk of developing ASD. The qualitative portion of this research 
project focused on the following aims: 
AIM 1: To determine themes and patterns of ASD from social media 
AIM 2: To understand the impact of social media on self-management of ASD with co-
morbid intestinal manifestations.  
AIM 3: To identify common symptoms and/or thematic elements used through social 
media 
The research seeks to answer the following research questions: 
1. What symptoms are expressed in recorded social media data related to ASDs? 
2. What are the themes related to ASD from social media? 
3. What are the facilitators and barriers of social media use in relation to ASD? 
Zonulin Pathway to Autism Spectrum Disorders 
Although the pathology between ASD and GI symptoms has not been clearly 
defined, the Autism Research Institute (2013) reported that up to 70% of ASD individuals 
suffer with GI issues. The most commonly reported symptoms of ASD are social 
impairment, communication difficulties, and repetitive and stereotyped behaviors. 
Additionally, symptoms of stomach pain, diarrhea, constipation, acid reflux, vomiting, 
bloating, and food allergies have been reported (Chaidez, Hansen, & Hertz-Picciotto, 
2014; Chandler et al., 2013; Mazefsky, Schreiber, Olino, & Minshew, 2013; National 
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Institute of Mental Health, 2011; Peters et al., 2014). Currently no diagnostic test is 
available to detect the presence or severity of ASD. 
Zonulin, pre-haptoglobin (HP) 2, is a complex protein structure that regulates 
epithelial tight junctions, allowing macromolecules to pass across cell membranes into 
the blood stream causing altered immune responses (Wang et al., 2000; Tripathi et al., 
2009). Although the relationship between ASD and the immune system is unclear, studies 
have identified associations between ASD and intestinal permeability (D’Eufemia et al., 
1996; De Magistris et al., 2010), and between ASD males and HP genotypes (Aposhian, 
Zakharyan, Chowdhury, & Avram, 2006). However, no studies reported in the literature 
have directly measured zonulin levels in ASD populations. Therefore, there is a need to 
determine the role of zonulin in ASD.  
The long term goal for this research is to provide a diagnostic assay that correlates 
the ASD diagnostic scale with different grades of GI severity. Based on pathophysiology 
of rising zonulin levels, the overall objective is to determine if there is a relationship 
between increasing or decreasing zonulin levels and ASD. The central hypothesis is that 
increases in zonulin concentrations in plasma are directly associated with ASD severity 
and that HP2-2 genotypes place an individual at a higher risk for developing ASD. The 
basis for this hypothesis is there is a correlation between intestinal permeability in 
individuals diagnosed with ASD, severity of ASD and symptoms of severe GI diseases 
(Adams, Johansen, Powell, Quig, & Rubin, 2011). Zonulin levels and haptoglobin 
genotypes will be determined from banked plasma and genomic deoxyribonucleic acid 
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(DNA) samples retrieved from the Greenwood Genetic Center. In order to test this 
hypothesis and accomplish the objectives, the following specific aims are proposed: 
Aim 4: Determine if zonulin levels in plasma obtained from individuals diagnosed 
with an ASD (Group 1) or newborns (Group 2) are different from zonulin levels in 
controls of healthy individuals matched by age and/ or gender (Group 3). Zonulin 
levels will be quantified using an enzyme-linked immunosorbent assay. The working 
hypothesis is that increased zonulin levels in plasma are directly associated with the 
presence and severity of ASD. 
Aim 5: Examine relationships between HP2 genotypes and increased zonulin levels 
in individuals with ASD (Group 1) or newborns (Group 2) compared to healthy 
controls matched by age and/or gender (Group 3). HP genotype will be determined 
using real time PCR. It is postulated that HP2-2 genotypes and zonulin will be increased 
in individuals with ASD.  
Aim 6: Determine if zonulin levels are good predictors between ASD and healthy 
control groups. It is postulated that increased zonulin levels will predict the presence of 
ASDs. 
The proposed research focused on identifying the role of zonulin or HP genotype in 
determining risk and severity of ASD. The results from this study will provide 
information for the development of a novel, quantifiable, diagnostic test to determine risk 
and/or severity of ASD. Additionally, the results will provide new mechanisms of interest 





 This chapter introduces the K2A framework and illustrates how each subsequent 
chapter brings this research from discovery to the translational phase. Chapter II 
synthesizes the literature in discovery of what is known and the gaps surrounding 
epithelial permeability related to zonulin and ASD. The information gained from the 
literature search identified a lack of zonulin testing among ASD individuals even though 
there were numerous publications which associated intestinal permeability and 
gastrointestinal symptoms with ASD. In order to fill this gap in literature, discovery and 
efficacy studies were planned and tested. Chapter III explores social media used to 
capture experiences, attitudes, and beliefs of individuals affected directly or indirectly by 
ASD and GI symptoms. The patterns and themes collected from mining social media 
supported future exploration. Chapter IV continued the discovery and efficacy studies by 
measure zonulin levels and haptoglobin genotype in individuals with ASD, newborns, 
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Tight junctions are protein complexes regulated by zonulin. The modulation of the tight 
junctions allows macromolecules to pass, causing a disruption in homeostatic 
mechanisms that play important roles in the development of immunity and disease. This 
paper will explain the physiological mechanisms and molecular pathways through which 
zonulin is or could be associated with symptoms or disease especially Autism Spectrum 
Disorders. The hypothesis is increased serum zonulin levels and comparisons of the 
physiological effects of zonulin and phenotypic assessment data can be used to implicate 
severity of disease states. Furthermore, a model of the zonulin pathway to disease is 
presented. 







Zonulin Pathway to Autism Spectrum Disorders 
Tight junctions (TJ), or zonulae occludentes, are continuous intercellular spaces 
between epithelial cells that are composed of more than 40 proteins (Anderson & Van 
Itallie, 2009; Fasano, 2001). Presently these proteins consist of the occludins, claudins, 
junctional adhesion molecules, and cytoplasmic plaque proteins necessary for structural 
functions (Nusrat, Turner, & Madara, 2000). Specifically TJs have two main functions: 
they serve as a barrier to protect against microorganisms by allowing only molecules with 
radii less than 15Å or 3.5kDa to pass into the cell, and they transport fluids, 
macromolecules, and leukocytes in and out of body compartments (Fasano, 2008; 
Fasano, A., 2011; Tripathi et al, 2009). Zonulin has been identified as a 47-kDa protein 
that regulates the opening and closing of TJs (Wang, Uzzau, Goldblum, & Fasano, 2000; 
Tripathi et al., 2009). The modulation of TJs allows macromolecules to pass into the 
bloodstream, thus playing an important role in the development of immunity and disease. 
The purpose of this paper is to explain the physiological mechanisms and molecular 
pathways through which zonulin regulates tight junctions. Furthermore, a model of the 
zonulin pathway to disease will be presented.  
The Zonulin Pathway 
Fasano et al. (1991) identified zonulin occludens toxin (ZOT), an enterotoxin 
produced by Vibrio cholerae, as a regulator of TJ. Diarrhea in patients testing negative 
for cholera toxin raised suspicion that another toxin produced by Vibrio cholerae may be 
present (Fasano et al., 1991). The results from the study by Fasano et al. (1991) indicated 
that ZOT increased intestinal permeability by altering the structure of intercellular TJ, 
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which allowed water and electrolytes to leak into the lumen of the small intestine 
resulting in diarrhea. A follow-up study by Baudry, Fasano, Ketley, & Kaper (1992) 
identified three ZOT genes CVD101, CVD108, and 395-N1. This study further defined 
ZOT as a 44.8kDa protein responsible for abdominal cramps, malaise, vomiting, 
headaches, and diarrhea. The zot gene was identified upstream of cholera toxin (ctx) 
genes with its terminal codon overlapping the ctx promoter (Baudry et al., 1992). ZOT 
binding was detected in jejunum and distal ileum, not the colon (Fasano, 2011; Fasano, 
2008; Di Pierro et al, 2001). Affinity purified anti-ZOT antibodies tested on mammalian 
tissue in ussing chambers identified zonulin as a eukaryotic homolog to ZOT (Wang et 
al., 2000). In the same study, a comparison of adult and fetal intestinal tissue by micro-
sequencing revealed that the N-terminal sequence of fetal zonulin 
(MLQKAESGGVLVQPG) is 60% identical to adult zonulin (EVQLVESGGXL) (Wang 
et al., 2000). The differences in the N-terminal sequences were believed to be due to fetal 
development, which also explained why the adult form regulated paracellular 
permeability while fetal forms regulated molecules between body compartments during 
embryogenesis (Wang et al., 2000). Since its first discovery, zonulin has been associated 
with several autoimmune diseases (Fasano, 2012). 
Fasano (2011) connected zonulin and its associated diseases to chromosome 16 
through two haptoglobin genes mapped to chromosome 16. A recent search in the 
University of California, Santa Cruz genome browser (http://genome.ucsc.edu/) using the 
human February 2009 (GRCh37/hg19) assembly identified the two genes as Haptoglobin 
(HP) mapped to chr16:72,088,508-72,094,955 and Haptoglobin-related protein (HPR) 
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mapped to chr16:72,097,125-72,111,145. Zonulin shows structural similarities to 
chymotrypsin and serine proteases which provide functions of reversibility, secretability, 
and presence in digestion, blood clotting, and complement (Fasano, 2011). The list of 
diseases linked to chromosome 16 included celiac disease, type 1 diabetes, asthma, 
multiple sclerosis, glioma, inflammation, and autism (Fasano, 2011; Swanwick, Larsen, 
Banerjee-Basu, & Banerjee-Basu, 2011).  
A review of the related literature as of July 2014 indicates a list of diseases that 
are suggested to show association with between intestinal permeability and the zonulin 
pathway. A search in Academic Search Complete using the terms “intestinal permeability 
AND zonulin” yielded 68 articles. A brief review of the titles and abstracts excluded 
articles discussing intestinal permeability without the mention of the zonulin or disease 
association with genotypes of haptoglobin. Nineteen articles discussed a probable 
association between disease and intestinal permeability via the zonulin pathway.  
Table 2.1  






Celiac Duerksen, Wilhelm-Boyles, Veitch, 
Kryszak, & Parry, 2010; Fasano et al., 2000;  
Tripathi et al., 2009; Wang et al., 2000 
Colitis Duerksen et al., 2010 
Crohn’s Disease Fasano , 2008 
Respiratory 
System 
Acute Lung Injury Matthay et al., 2003 
Acute Respiratory 
Distress Syndrome 
Matthay et al., 2003 










Schizophrenia Paterson et al., 2007 
Alzheimers Liu, Wang, Zhang, Wei, & Li, 2012 
Multiple Sclerosis Fasano, 2011 




Jayashree et al., 2014; Moreno-Navarrete et 
al., 2012  
Type 1 Diabetes Sapone et al., 2006; Watts  et al., 2005 
Systemic Lupus 
Erythematosus 
Pavon et al., 2006 
Infectious 
Diseases 
HIV Liu et al., 2012 
HCV Fasano, 2011 
Sepsis Klaus et al., 2013 
Cancers Breast Cancer Russo et al., 2013 




Pancreatic carcinoma Fasano, 2011 
Table 2.1 Diseases Associated with Zonulin.   
Zonulin exists in two forms: an un-cleaved form known as pre-haptoglobin 2 (pre-
HP2) that binds to proteinase activated receptor 2 (PAR2) and epidermal growth factor 
receptor (EGFR), and a form cleaved by trypsin at Arg
161
 that seeks to bind hemoglobin 
(Tripathi et al., 2009; Fasano, 2012). The initial studies indicated that the two different 
forms of zonulin yield two different functions due to the folding of the protein, with only 
the un-cleaved form affecting epithelial permeability (Fasano, 2012; Tripathi et al., 
2009). Current research suggests that both forms of zonulin affect permeability (Rittirsch 
et al., 2013). Additional research is needed to determine if permeability resulting from 
increased zonulin levels is due to tissue or model specific responses. Zonulin is heavily 
concentrated in the endoplasmic reticulum (ER) and golgi (Drago et al., 2006). The un-
cleaved form of zonulin can be detected in human serum at a range of 80-208µg/mL 
(Tripathi et al., 2009). 
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Recent studies of micro-ribonucleic acid (miRNA) have shed light on 
transcription of haptoglobin. The discovery of an acute-phase response regulatory 
pathway shows that micro-RNA-18a can enhance interleukin 6 (IL-6) release from 
monocytes and immune cells causing phosphorylation and dimerization of signal 
transducer and activator of transcription 3 (STAT3) in the liver (Brock, Trenkmann, Gay, 
Gay, Speich, & Huber, 2011; Gauldie, Richards, Harnish, Lansdorp, & Baumann, 1987; 
Wegenka, Buschmann, Lutticken, Heinrich, & Horn, 1993). STAT3 homodimers then 
move to the nucleus and bind to promoter regions of deoxyribonucleic acid (DNA) to 
stimulate transcription of IL-6 target genes haptoglobin and fibrinogen (Brock et al., 
2011). Intracellular feedback loops maintain the expression of STAT3 for transcription 
(Brock et al., 2011).  The involvement of STAT3 in transcription of haptoglobin suggests 
that mutations in STAT3 may lead to interruptions in the zonulin pathway and maybe 
associated with other diseases and conditions. Research is needed to understand specific 
factors related to translation of RNA to zonulin protein.  
To better understand and develop associations with disease it is important to begin 
with examining what triggers activation of the zonulin pathway. Activation of zonulin 
occurs through exposure to gliadin, bacteria, and viruses (Drago et al., 2006; Fasano, 
2012, Guttman & Finlay, 2009). Gliadin is one of two protein products of gluten. Gliadin 
binds to chemokine (C-X-C motif) receptor 3 (CXCR3) which recruits an adapter protein 
MyD88 increasing intestinal permeability and activating the release of zonulin (Lammers 
et al., 2008). Zonulin interacts with different surface receptors to activate phospholipase 
C, hydrolyzing phosphatidyl inositol into inositol 1,4,5-tris-phosphate (PPI-3) and 
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diacylglycerol (DAG) (Fasano, 2001; Mowat, 2003; Brandtzaeg et al., 1989). DAG and 
PPI-3 mediate protein kinase C through different mechanisms. DAG can directly bind to 
protein kinase C, whereas PPI-3 causes the release of intracellular calcium leading to 
protein kinase C mediation (Drago et al., 2006; Visser, Rozing, Sapone, Lammers, & 
Fasano, 2009). In both cases, protein C mediation leads to polymerization of intracellular 
actin filaments leading to the reorganization and restructure of the cytoskeleton and 
epithelial barriers (Drago et al., 2006; Visser et al., 2009). Actin filaments function 
mainly in cell growth and shape. When actin filaments reorganize they can form fiber-
like cables to provide shape and purpose to nerve cells or they can form track-like 
structures to transport molecules or microbial materials (Ivanov et al., 2010; Singh et al., 
2010).  
The reorganization of actin filaments can be visualized using human Caco2 cells 
and rat IEC6 cells. Caco2 cells from human colorectal adenocarcinoma in monolayers 
provide a model for small intestine enterocytes and tight junctions. One study exposed 
these two cell groups to gliadin to view the redistribution of proteins that make up the TJ 
complex (Drago et al., 2006). It is the N-terminal sequence of pre-HP2 that shares a 
common motif (GGVLVQPG) with the active ZOT fragment, binding to specific surface 
receptors that activate signaling pathways (Fasano, 2008).  
Another study found the N-terminal sequences of Zot/zonulin binding proteins 
showed dose dependent binding in human brain, intestine, and heart tissues suggesting 
disease association with increased zonulin levels in these systems (Lu, Wang, Uzzau, 
Vigorito, Zielke, & Fasano, 2000). The serine protease characteristics and growth 
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hormone-like structures of pre-HP2 induce protease-activated receptor 2 (PAR2) 
dependent transactivation of epidermal growth factor receptor (EGFR) (Lammers et al., 
2008; Fasano, 2012). Six spatially conserved cysteine residues in the ß-chain of pre-HP2 
form three intramolecular disulfide bonds which are involved in epidermal growth factor 
activity. Concentrations of pre-HP2 ≥15 µg/mL are enough to activate EGFR (Tripathi et 
al., 2009). Activation and mutations in EGFR have been associated with lung 
adenocarcinoma, non-small cell lung carcinoma, breast cancers, colon cancers, and 
response to radiation and drug therapies (Ellina et al., 2014; McCarty, 2014; Nechushtan 
et al., 2014; Pan et al., 2014; Suda et al., 2014). Therefore, the association between 
zonulin and EGFR suggests involvement with cancers and drug therapies (McCarty, 
2014; Suda et al., 2014). 
 The other triggers of zonulin activation occur by the unique TJ modifications 
caused by bacteria and viral pathogens (Guttman & Finlay, 2009). Figure 2.1 is a 
representation published by Guttman and Finlay (2009) demonstrating how different 










Figure 2.1  
Bacteria and Virus Alteration of Tight Junctions 
 Figure 2.1 Bacteria and Virus Alteration of Tight Junctions. The figure shows how 
bacteria and viral pathogens alter the tight junctions (Guttman & Finlay, 2009). 
The success of a bacteria or virus to penetrate the epithelial barrier or disassemble  
the TJ results in infection and inflammatory response (Guttman & Finlay, 2009). The 
attack on the epithelial barrier is two-sided. The lumen side is penetrated and altered 
through exposure to pathogenic organisms and toxins while the mucosal side is exposed 
to immune cell secretions of cytokines, proteases, and reactive oxygen species (Ivanov et 
al., 2010). Enteric microorganisms induce luminal secretion of zonulin in the small 
intestine and open the TJ (Fasano, 2008). Hydrostatic pressure gradients form, increasing 
water secretions into the lumen which flush bacteria from the intestine (Fasano, 2001; 
Fasano, 2008). These two mechanisms of zonulin activation provide a foundation to 




Physiological System Involvement 
Cell models, animal models, and human studies have identified physiologic 
mechanisms of zonulin and their association with disease. A review of the literature 
identifies four physiological systems and disease models that are disrupted due to 
increased epithelial permeability: Gastrointestinal (GI), Neurological, Oncology, 
Endocrine, and Respiratory Systems. Diseases associated with increased levels of zonulin 
have been suggested to be auto-immune; but, there is reason to consider that symptoms 
related to increased zonulin levels may be seen in other diseases not yet classified as 
having an autoimmune component (Fasano, 2011; Fasano, 2012). Further research is 
needed to elucidate these other diseases. However, symptoms and mechanisms related to 
increased zonulin have been described in GI, neurological, endocrine, and respiratory 
systems.  
Gastrointestinal System 
Zonulin was first generally identified as a regulator of intestinal permeability and 
has since been implicated in the pathogenesis of celiac disease and colitis (Wang et al., 
2000; Fasano et al., 2000; Duerksen, Wilhelm-Boyles, Veitch, Kryszak, & Parry, 2010; 
Cipriani et al., 2011). In cases of Celiac disease, increased permeability in the small 
intestine allows gliadin to cross the lamina propria, activate an intramucosal immune 
cascade, and result in villous destruction and/or crypt heterotrophy (Duerksen et al., 
2010). The intramucosal immune cascade is a first-line series of immune interactions for 
stimulation of immunoglobulin A (IgA) in response to foreign particles. Studies using 
real-time polymerase chain reaction (PCR) to quantitate zonulin expression levels found 
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increases with celiac disease activity (Tripathi et al., 2009). A study comparing 
permeability, antibody testing, and diet from zonulin levels in tissue found that zonulin is 
constitutively up-regulated in celiac disease patients, remaining elevated but not 
correlating well with histology (Duerksen et al., 2010). Comparisons between lab tests 
showed 100% sensitivity and specificity in antibody levels predicting abnormal of small 
intestine tissue compared to only 83% for permeability testing using lactose mannitol 
(LM) tests (Duerksen et al., 2010).  
To date, all of the tests associating intestinal permeability with ASD have been 
measured using LM tests (De Magistris et al., 2010; D’Eufemia et al., 1996). The LM test 
involves oral administration of a solution of mannitol and lactulose with subsequent 
assessment of small intestine absorption measured by a six hour urine collection (Cooper, 
1984). For children, LM testing has been used to determine allergies and intestinal 
permeability, but the methods of oral administration and collection are very difficult to 
obtain due to the use of diapers and inability of children to anticipate the need for 
urination and bowel movements. Enzyme linked immunosorbent assay (ELISA) testing 
of zonulin may provide novel methods for measuring intestinal permeability (Flanagan et 
al., 2014).  
Comparison of tests showed significant relationships between permeability and 
serum zonulin levels in patients with destructive intestinal histology, but elevated levels 
of zonulin with normal intestinal histology limited the use of zonulin for clinical 
monitoring (Duerksen et al., 2010). Tissue specific differences in the ubiquitous 
expression levels of zonulin, long term exposure rates to increased serum zonulin, and 
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gene activation patterns associated with zonulin may explain why zonulin has not been 
useful in clinical monitoring. A study of zonulin levels in patients with gastroesphogeal 
reflux disease and normal healthy controls found ubiquitous expression of zonulin at 2.2-
3.6ng/µg in the stomach and esophagus (Wex et al., 2009).  The ubiquitous expression of 
zonulin is thought to be a result of its role in epithelial barrier function from pathogens. 
Further research is needed to identify gene interactions with serum zonulin and to 
determine if zonulin levels can be used for clinical monitoring.  
Several studies have examined gliadin activation of zonulin and how serum 
zonulin levels can monitor celiac disease. A study by Fasano et al. (2000) showed that 
IgA anti-zonulin levels are increased in acute phase celiac disease at 21% (p<0.0001) but 
no increase is seen in IgG levels (Fasano et al., 2000). Baseline levels of zonulin remain 
increased for celiac patients compared to those in remission and healthy controls; dietary 
intervention always resulted in a return to baseline zonulin levels after 3-6 months of 
implementation (Fasano et al., 2000). The return to baseline levels indicate that increased 
permeability is reversible and dietary intervention may be a possible intervention upon 
presentation of disease. 
Zonulin associated with colitis has also been studied in mice models. Bile acid 
receptor (GPBAR-1) knockout mice demonstrated increased expression of zonulin-1 
mRNA, decreased expression of occludin messenger ribonucleic acid (mRNA) (p <0.05), 
and altered sub-cellular distribution along the apical border of colonocytes and vascular 
endothelial cells (Cipriani et al., 2011). Additionally, there was an increase in CD8+cells 
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and severity of colitis in the GP-BAR1 knockout mice associated with diarrhea and loss 
of mucous cells (Cipriani et al., 2011).  
Neurological System 
The blood brain barrier (BBB) is a complex system of membrane proteins that 
form TJ which facilitate control of the flow of molecules in and out of the central nervous 
system (Liu, Wang, Zhang, Wei, & Li, 2012). Physiological conditions associated with 
changes in the BBB include Alzheimer’s disease, chronic inflammation, diabetes 
mellitus, human immunodeficiency virus, and abuse of drugs such as methamphetamine, 
cocaine, and morphine (Liu et al., 2012). Affinity column purification identified that 
zonulin binds to human brain tissue (Lu et al., 2000). This implies that zonulin may 
regulate the BBB allowing substances interrupt barrier function and alter the integrity of 
the actin filaments. In an in vitro BBB model using rat brain microvascular endothelial 
cells (RBMECs), zonulin increased the transmigration of human neural progenitor cell 
lines across the RBMECs and increased epidermal growth factor function (Diaz-
Coranguez et al., 2013). This study was the first to show that pre-HP2 binds to a surface 
receptor that opens the BBB and activates a signal pathway that activates phospholipase 
C and protein kinase C, polymerizes actin, and contracts the perijunctional action-myosin 
ring allowing zonulin to alter the shape and function of nerve cells (Diaz-Coranguez et 
al., 2013; Ivanov et al., 2010). The role of zonulin in the BBB targets it in processes that 
direct migration of neural stem cells to sites of injury, which indicate its importance in 





The endocrine system synthesizes and secretes chemicals into the body to regulate 
growth, metabolism, and sexual development (Coelho, Oliveira, & Fernandes, 2013). 
Within this system, increased zonulin levels have been associated with obesity and type 2 
diabetes mellitus (Fasano et al., 2000; Jayashree et al., 2014; Moreno-Navarrete, Sabater, 
Ortega, Ricart, & Fernandez-Real, 2012; Zak-Gołąb et al., 2013). Obese individuals have 
a significantly higher concentration of zonulin than non-obese individuals (12.5±4.6 to 
9.3±5.1, p=0.007) (Moreno-Navarrete et al., 2012). Associations between increased 
levels of zonulin and obesity were specifically related with increases in body mass index, 
waist to hip ratio, fasting insulin, fasting triglycerides, uric acid, IL-6, low levels of high-
density lipoprotein-cholesterol, and decreased insulin sensitivity (Moreno-Navarrete et 
al., 2012). Another study by Zak-Gołąb et al. (2013) evaluated 50 obese individuals 
compared to 30 normal weight individuals. These researchers found that obese 
individuals had a mean zonulin level of 8.2ng/mL (p < 0.001) compared to a mean 
zonulin level of 5.4ng/mL in normal weight controls (Zak-Gołąb et al., 2013). The study 
also found positive correlations between plasma zonulin levels and age (r = 0.43, p < 
0.001), body mass (r = 0.30, p < 0.01), body mass index (r = 0.33, p < 0.01), fat mass (r = 
0.31, p < 0.01) and fat percentage (r = 0.23, p < 0.05) (Zak-Gołąb et al., 2013).  
A study by Jayashree et al. (2014) confirmed elevated circulating serum zonulin 
levels (796 ± 55pg/mL, p <0.001) in individuals with type 2 diabetes mellitus compared 
to healthy controls (3.96 ± 0.16pg/mL). These studies suggest that zonulin may play a 
role in metabolic disturbances. Further research is needed to determine if it is due to 
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increased intestinal permeability, loss of intestinal barrier function, or disruption in 
metabolic pathways.  
Relationships between zonulin levels and diabetes have been explored using both 
animal and human studies. Animal models using rats determined relationships between 
zonulin, intestinal permeability, and glucose levels. Watts et al. (2005) found serum 
zonulin levels were correlated with intra-luminal zonulin, increasing prior to increases in 
glucose and development of type 1 diabetes. In the rat model studies, type 1 diabetes 
developed 25 days after zonulin increased intestinal permeability (Watts et al., 2005). In 
patients with type 1 diabetes, increased zonulin levels (0.83±0.05ng/mg) were higher than 
their “normal” relatives (0.62±0.07ng/mg) and healthy controls (0.21±0.02ng/mg) 
(Sapone et al., 2006). No correlations were found between serum zonulin levels and age, 
sex, diagnosis of type 1 diabetes, duration of type 1 diabetes, daily insulin dose, 
hemoglobin A1c, or serum glucose levels (Sapone et al., 2006). This study provided 
evidence that increased intestinal permeability of type 1 diabetes was correlated to 
increased serum zonulin levels (Sapone et al., 2006).   
Respiratory System 
The development of acute lung injury (ALI) and acute respiratory distress 
syndrome (ARDS) result from pneumonia, aspiration, trauma, sepsis, and associated 
disorders such as pancreatitis and drug overdose (Matthay et al., 2003). Lung 
permeability is typically measured by albumin leak to indicate severity as failure of 
treatment can lead to alveolar edema or hemorrhage (Rittirsch et al., 2013). A recent 
study exploring the unidentified molecular mechanisms of ALI found that administration 
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of zonulin antagonist AT-1001 reduced albumin leak by 67%; reduced the number of 
leukocytes (mostly neutrophils) by 25%; and reduced proinflammatory cytokines IL-6 
and tumor necrosis factor  (TNF-) (Rittirsch et al., 2013). Exposure to both forms of 
zonulin showed increased lung permeability in mouse models. Rittirsch et al. (2013) 
found that 20µg of pre-HP2 indicated a 3.2-fold increase in lung permeability and HP2 
showed a 2.6-fold increase in lung permeability. The addition of zonulin to human serum 
activated complement demonstrating its role in barrier function (Rittirsch et al., 2013).  
Links Between Zonulin and ASD 
Zonulin associations with disease are actively being explored to better understand 
the molecular pathways and mechanisms of proteins. Hallmarks of cancer and 
pathopysiological changes that are only characteristic of cancer show involvement of 
zonulin in different cancers. This work has evolved from effecting the onset of diarrhea 
during chemotherapy to zonulin involvement in therapy and radiation treatments (Russo 
et al., 2013). A study of breast cancer patients showed that GI symptoms (29% with 
diarrhea) increased on day 14 of chemotherapy compared to no GI symptoms at baseline 
(29.86±1.27 and 24.7±0.94, p=0.02) (Russo et al., 2013). The GI symptoms were 
accompanied by a day 14 increase in intestinal permeability (0.067%, p=0.001) (Russo et 
al., 2013). Over the 21 day chemotherapy treatment, total serum zonulin levels did not 
change; however, circulating levels of glucagon-like peptide 2 (GLP-2) and EGF showed 
significant decreases (p=0.0044 and p=0.004 respectively) until reaching a plateau at 
which point no further decrease was observed (Russo et al., 2013). The stability of 
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zonulin levels during treatment indicates they are independent of chemotherapy (Russo et 
al., 2013).  
The study of zonulin levels in glioblastomas showed that zonulin expression 
controls intercellular communication in two ways: increased v-kit Hardy-Zuckerman 4 
feline sarcoma viral oncogene homolog (c-kit) expression and activation responsible for 
tumor aggression and effectiveness of tyrosine kinase inhibitor therapies (Skardelly, 
Armbruster, Meixensberger, & Hilbig, 2009). Results from human glioma studies 
provided evidence that zonulin expression correlated with tumor aggression more 
specifically than expression of c-kit, suggesting that zonulin levels may indicate the 
degree of disruption in the blood brain barrier and blood vessel walls (Skardelly et al., 
2009). Further research is needed to determine associations between zonulin and genomic 
mutations that lead to cancer and suggestive therapy options. 
A particular area of interest is the role of zonulin in Autism Spectrum Disorders. 
Autism Spectrum Disorder (ASD) describes an array of developmental brain disorders 
that are associated with multiple levels of symptoms, cognition, language, and behavior 
presentations. The Centers for Disease Control and Prevention (2014) indicates that 1 in 
68 children in the United States have ASD. Symptoms of ASD include social 
impairment, communication difficulties, and repetitive and stereotyped behaviors 
(American Psychiatric Association, 2013). However, additional symptoms have been 
reported of food allergies, acid reflux, vomiting, bloating, stomach pain, diarrhea, and 
constipation (U.S. Department of Health and Human Services, National Institutes of 
Health, 2011). No studies in the literature report serum zonulin measurements of 
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individuals diagnosed with ASD, but many connections can be made based on 
overlapping mechanisms.   
The GI and neurological systems demonstrate two examples that point toward the 
involvement of the zonulin pathway. Autism spectrum disorders have long been 
associated with GI issues. According to the Autism Research Institute (2013), 70 % of 
children with ASD have GI symptoms; however, these are sometimes difficult to 
recognize due to communication difficulties between the child, parents and healthcare 
providers. The spectrum of phenotypic expression and gene interactions related to ASD 
and GI issues make GI or ASD disorders challenging to diagnose.  In a large registry-
based study of 589 individuals, Wang, Tancredi, & Thomas (2011) reported 42% of 
children with ASD had GI problems including constipation and diarrhea compared with 
their unaffected siblings (12%). Interestingly, ASD and GI disorders, such as celiac 
disease, have increased at approximately the same rates over the past 10 years to a 
prevalence of 1 in 88 children (Centers for Disease Control and Prevention, 2012; Rubio-
Tapia, Ludvigsson, Brantner, Murray, & Everhart, 2012). Table 2.2 identifies symptoms 
related to GI disorders and diagnostic evaluations in patients with ASD (Buie et al., 
2010).  
Table 2.2  
Diagnostic Evaluation of GI Symptoms and Disorders in Individuals with ASDs 
Symptoms Associated Gastrointestinal Disorder 
Sleep disturbance GERD 
Self-injurious behavior, tantrums, 
aggression, oppositional behavior 
Constipation, GERD, gastritis, intestinal 
inflammation 
Chronic diarrhea Malabsorption, maldigestion 





Abdominal discomfort Constipation, GERD, intestinal 
inflammation, malabsorption, maldigestion 
Flatulence or bloating Constipation, food allergies, enteric 
infection 
Any or all of the above Familial adenomatous polyposis, irritable 
bowel syndrome 
Table 2.2 Diagnostic Evaluation of GI Symptoms and Disorders in Individuals with 
ASDs adapted from Buie et al., 2010. 
 
One of the symptoms, the amount of undigested food, raises concern for passage 
through the TJ and the physiological effects it may have on the body. Undigested food in 
the form of large immunogenic peptides or intact proteins may reach the lumen of the 
small intestine due to evasion of gastric fluid and proteolytic enzyme hydrolysis (Menard, 
Cerf-Bensussan, & Heyman, 2010). Undigested food particles may pass through the TJ 
stimulating an immune response. Similarly, drug molecules may pass through the tight 
junctions of the intestine leading to immune reactions, disease, or toxicity (Ju & Uetrecht, 
2002). Drugs are classified based on solubility and permeability according to the 
Biopharmaceutics Classification System; permeability determination is made from 
pharmacokinetic studies, in vivo intestinal perfusion, in vitro permeability using tissue 
biopsies, and Caco2 monolayer studies (Chavda, Patel, & Anand, 2010).  
The basis for determining zonulin expression levels in individuals with ASD is 
found by precedent of intestinal permeability in individuals diagnosed with ASD and 
correlations between severity of autism spectrum disorders and severe gastrointestinal 
diseases. D’Eufemia et al. (1996) identified that 43% of autistic patients displayed altered 
intestinal permeability using lactulose/mannitol (LM) tests. D’Eufemia et al. (1996) 
speculated that intestinal permeability increased the passage of food peptides through the 
gut leading to subsequent behavioral abnormalities.  
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De Magistris et al. (2010) performed tests on 90 children with Autism Spectrum 
Disorder and 146 of their first-degree relatives. Results revealed 36.7% of ASD patients 
and 21.2% of their first-degree relatives have abnormal intestinal permeability (De 
Magistris et al., 2010). Once again, intestinal permeability was determined by LM tests. 
For ASD patients and their first-degree relatives there was a 2-to 3-fold increase in 
lactulose compared with mannitol recovery (De Magistris et al., 2010). Interestingly, 
most of the ASD patients and relatives were negative for antibodies or antigens to food 
allergies (De Magistris et al., 2010). The toxic reactions without the presence of 
antibodies or antigens may indicate that zonulin association with gastrointestinal disease 
is a result of constitutive action of the toxic effects of the protein at increased levels.  
Furthermore, the correlation between zonulin levels and severity of autism is 
supported by the results from Adams, Johansen, Powell, Quig, & Rubin (2011). These 
researchers found that children with more severe forms of autism are likely to have more 
severe gastrointestinal symptoms. Gastrointestinal symptoms were measured based on a 
GI severity index using a combined score of constipation, diarrhea, stool consistency, 
stool smell, flatulence, and abdominal pain. Children with higher Autism Treatment 
Evaluation Checklist scores had gastrointestinal severity index scores greater than 3 
(p=0.00002) (Adams et al., 2011). 
Neurological mechanisms are of major importance in linking ASD and zonulin, 
and supporting correlation between increased zonulin levels and severity of neurological 
symptoms. The study by Skardelly et al. (2009) implicated zonulin expression levels in 
disruption in the BBB and blood vessel walls suggested that zonulin may be correlated 
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with neurological levels of severity in individuals with ASD. Studies of zonulin may help 
determine if disruption of the BBB leads to disruption of brain development and 
signaling occurs in utero from maternal immune activation or during infancy. A 
connection can already be made through signal transducer and activator of transcription 
3 (STAT3) activation by IL-6. Using animal models, Parker-Athill et al. (2009) found that 
IL-6 mRNA levels remain elevated up to 24 weeks after birth suggesting in utero 
inflammatory pathogenic effects. Such a connection could lead to development of 
diagnostic testing for ASD and early diagnosis.  
Conclusion 
 Identification of zonulin as a modulator of intestinal permeability has expanded 
the understanding of tight junctions. Research has implicated increases in zonulin to 
physiological effects in the Gastrointestinal, Neurological, Respiratory, Endocrine 
systems, and oncological diseases. The ability of zonulin to allow macromolecules and 
antigens to pass through the TJs in the intestine and the BBB challenge classical theories 
of inflammatory pathogenesis based solely on genetics and environmental triggers 
(Fasano, 2011). The regulation and reversal of intestinal permeability by zonulin 
proposes a new theory that pathogenesis, in general, is not self-perpetuating but can be 
interrupted (Fasano, 2011). Based a review of the literature published thus far, a model is 
proposed that uses increased serum zonulin levels and comparisons of the physiological 
effects of zonulin and phenotypic assessment data to implicate severity of disease states. 




Figure 2.2  
New Zonulin Model of Pathogenesis  
  
Figure 2.2 illustrates the zonulin pathway that produces symptoms and diagnosis of 
disease.  
Additional research is needed to understand the zonulin pathway and its 
associated diseases. It will be important to identify ranges of zonulin, highlight specific 
symptoms or a phenotypic threshold for disease, identify gene interactions and 
environmental triggers, and indicate zonulin regulation of drug metabolism. The need for 
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Autism spectrum disorder (ASD) is a developmental disorder that is accompanied 
by an array of symptoms affecting behavior, communication, cognition, and multiple 
organ systems. Early diagnosis of ASD is being sought to reduce the severity of 
symptoms, increase daily function, and maintain quality of life. Social media such as 
Twitter, Facebook, LinkedIn, chat rooms, and blogs present resources to the public that 
allow them to capture experiences and symptoms of autism or other diseases in real time. 
This study explores and captures self-reported material posted in social media using 
Radian6 to identify patterns and themes related to autism and GI symptoms for the 
purpose of translating that knowledge into healthcare applications at the individual and 
corporate levels.  














Exploring Autism and GI Symptoms using Radian6  
Autism spectrum disorder (ASD) is a developmental disorder that is accompanied 
by a myriad of symptoms affecting behavior, communication, cognition, and multiple 
organ systems (American Psychiatric Association, 2013). Many genes have been 
implicated with risk associated with disorder development, but the etiology of autism 
remains unknown (Gilling et al., 2013; Handrigan et al., 2013; Liu et al., 2013; Sarachana 
& Hu, 2013). Focus has recently moved toward early detection of ASD, which is 
pertinent to minimize symptoms and maintain quality of life. With no diagnostic test 
available, early detection relies autism rating scales and evaluation checklists that rely on 
behaviors and observations made by parents, caregivers, or healthcare professionals 
(Geier, Kern, & Geier, 2013; Nah, Young, & Brewer, 2014).  
The development of social media provides an open platform to witness a variety 
of self-reported experiences related to autism. A recent study by Mazurek (2013) 
identifies 79.6% of 108 ASD individuals used social media sites to connect with others. 
In another study, Mazurek and Wenstrup (2013) found children with ASD spent little 
time using social media and more time playing video games than their siblings who 
followed typical growth and development guidelines. Additionally, a qualitative study 
was performed using chat logs of twelve young people diagnosed with attention-
deficit/hyperactivity disorder and ASD (Ahlstrom & Wentz, 2014). The chat logs 
identified two themes of ‘fighting against an everyday life lived in vulnerability” and 
“struggling to find a life of one’s own” (Ahlstrom & Wentz, 2014). These studies using 
internet and social media suggest that these devices or applications may provide methods 
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for diagnosing, monitoring, or treating ASD (Ahlstrom and Wentz, 2014; Mazurek, 2013; 
Mazurek & Wenstrup, 2013). Topics focusing on communication, management, and 
health related concerns dominate social media and findings indicate that after initial 
participation, engagement of social media decreases over time with autistic individuals 
(Hong, Yarosh, Kim, Abowd, & Arriaga, 2013).  
Studies surrounding autism and gastrointestinal (GI) symptoms have focused 
primarily on self-report from questionnaires and surveys (Kang, Wagner, & Ming, 2014). 
Internet based approaches to ASD intervention consistently indicate increases in quality 
of life (Garcia-Villamisar and Dattilo, 2010; Wentz et al., 2012). Evidence suggests that 
facilitating interaction with media, exercise, games, crafts, and events decreases stress 
levels and increases quality of life for individuals with ASD (Garcia-Villamisar and 
Dattilo, 2010; Wentz et al., 2012). A review of the related literature was unable to 
identify publications directly mention using social media as a translational tool to study 
ASD for the purpose of targeting pathways of disease mechanisms or for developing new 
interventions and approaches. The purpose of this study was to explore and capture self-
reported material posted in social media in order to identify patterns and themes related to 
autism and GI symptoms for the purpose of knowledge translation to healthcare 
application.  
Methodology 
A non-experimental exploratory study was conducted using Radian6 to mine 
social media data. Radian6 software allows for data mining across multiple social media 
outlets such as Facebook, Twitter, blogs, and Media. Data was captured at the end of 
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each month from September 1, 2013 to November 30, 2013. Parameters in Radian6 were 
set to collect only data in the English language in the United States (U.S.). All media 
types were included. The study data was present in the public domain, free of 
subscription or login requirements. Following the rules of repeated entry elimination by 
elastic matching identification, data was excluded if it was a repeated entry having ≥90% 
identity with a previous post (Zhao et al., 2013). In addition, information was excluded if: 
(1) the source required membership dues, site registration, or login; (2) the hit was an 
advertisement, sub-headline only, or random text with no contextual information; or (3) 
the entry contained ≥ 90% sexually related or derogatory comments or content. 
Filtering Criteria 
Search terms entered in Radian6 were based on a literature review of 
gastrointestinal symptoms commonly seen in ASD individuals. Search terms of GI 
symptoms were combined with “AND CONTATINS AUTISM” and were separated with 
“OR.” For example, the search terms read (“food allergies” AND CONTAINS “autism”) 
OR (“nausea” AND CONTAINS “autism”). The search strand continued until all GI 
symptoms had been added. See Table 3.1 for a list of GI symptoms seen in patients with 
autism, which were used as keywords. 
Table 3.1  
GI Symptom Keywords for Radian6 Search Criteria 




5. Infection (Bacteria, parasite, OR yeast) 
6. Bloating OR Flatulence 
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7. Abdominal pain 





The keywords were based on common symptoms related to the GI system and ASD. It 
was difficult to define a boundary of vocabulary used by the public for autism or GI 
problems due to the spectrum of symptoms. The keywords provide a boundary within 
social media to reduce the data collection from over a million hits using only autism as a 
search term, to a collection of 6878 data entries.  
Data Analysis 
Using the specified filtering criteria, Radian6 yielded 6878 entries. The first stage 
of data analysis indicated that the majority of social media information was being 














Dispersion of Information in Social Media 
 
Figure 3.1 Dispersion of Information in Social Media. [The pie graph above shows the 
percentage of hits per media outlet across a total of 6878 entries from Radian6 for months 
September, October, and November. The coded data was not used for the dispersion 
diagram in order to represent which type of social media would most likely be seen by 
the public when searching for information. The information shows that Facebook tends to 
be the most common form of social media discussing autism and GI symptoms. Radian6 
also produced comment counts for each month of data collection. Across all three months 
of data, interventions were most frequently commented on, with topic of gluten being in 
the top 2 for all three months. Baby development was also included within the top 5 
topics of comment across all three months.]  
In order to prepare the data for analysis, it was exported from Radian6 into Excel 
in the form of a .csv file at which point each entry underwent manual examination. Each 
entry was accessed in full via its corresponding web address. A research team member 
read the entry and coded it based on contents. Entries were tagged for deletion if they did 

























in the identification of repeated entries, which could be identified by web address, 
contents, or author. Entries failing to meet the criteria were discarded before upload into 
QSR International’s NVivo 10 software for further analysis. Of 6878 entries identified in 
social media, only 1930 hits contained contextual information related to autism and GI 
symptoms. The remaining 1930 social media hits after initial cleaning in Excel were 
dispersed among several media providers. The top four media providers included 
Facebook (49.9%), wordpress (13.7%), generic blogs (11.2%), and forums (10.5%). 
Twitter posts contained the most repeated content which was tagged for removal from the 
data set.  
Manual examination of the 1930 hits in Excel yielded 20 coded categories. These 
categories included links to “autism”, “pathology”, “no links to autism”, “symptoms”, 
“interventions”, “consequences”, “feelings”, “siblings”, “age at diagnosis”, “age at 
onset”, “coping mechanisms”, “testing”, “intestinal permeability”, “co-morbid diseases”, 
“retraction of autism diagnosis”, “lacks deficits needs”, “questioning”, “family history”, 
“ASD improvements”, and “indications of pharmacogenomic testing”. Each entry was 
coded for one or more category based on the contextual information. The “no links to 
autism” category was included to capture all stake holder points of view, and to address 
the final quantity of these hits was enough to statistically support the null hypothesis. 
After coding three months of information, it was determined that some categories could 
be collapsed to better represent the data. The “co-morbid diseases” category was 
combined with the “symptoms” category, the “retraction of autism diagnosis” category 
was combined with “ASD improvements,” and cases within the “indications of 
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pharmacogenetic testing” category were re-coded to either interventions or symptoms. 
The final category of symptoms was intended to look at all symptoms associated with 
ASD and to answer the research question, “what symptoms are expressed in recorded 
social media data related to ASDs?” Additionally, the categories were used to identify 
themes related to ASD from social media. Categories of “lack deficit needs”, “ASD 
improvements”, and “interventions” were intentionally directed at answering the research 
question, “what are the facilitators and barriers of social media use in relation to ASD?” 
The re-categorized data was uploaded into QSR NVivo for further content analysis.  
In NVivo, tree nodes were created to catalogue categories into hierarchical 
structures, and other categories were collapsed into more generalized categories. In total, 
18 categories emerged from the 1930 social media hits. The 18 categories had a 
combined 24,127 coded references. The term “coded references” refers to words or 
phrases from each hit that are coded to a particular node or multiple nodes. The term 
“node” is used synonymously with category. The final categories included “siblings”, 
“feelings”, “proposed links”, “family history”, “pathology”, “coping mechanisms”, 
“consequences”, “media provider”, “no link to autism”, “lack deficit needs”, “age at 
onset”, “intervention”, “questions”, “improvements”, “symptoms”, “age at diagnosis”, 
“abilities”, and “quotes”. The following includes the major findings for each category.  
Results 
Siblings 
The category of “siblings” contained 64 out of 1930 hits across the three months 
with 1943 coded references. Siblings were defined as a brother or sister relationship, 
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adopted or blood relative related to an individual with autism. The references coded into 
the “sibling” category referred to a number of children in the family identifying affected 
or not, gender, or symptoms. The most frequently mentioned terms were words that 
indicated autism (autism, ASD, or affected) was present among children (children, kids, 
sibling, or siblings) for weighted percentages of 15.86% (55 counts) and 10.37% (36 
counts) respectively. Most families had one or two children with both terms represented 
at 3.17% (11 counts) each and of these, boys were most commonly represented (2.59% or 
9 counts). These findings lend support to the prevalence that boys are five times more 
likely to be affected by autism than girls (Centers for Disease Control and Prevention, 
2014). The word cloud generated by QSR NVivo for “siblings”, as shown in Figure 3.2, 













The size of each word in the word cloud is proportional to the number of times 
that word appears in the node. The word count also increases the weighted percentage a 
word has within a node. The word cloud provides a visual interpretation of the numerical 
values without having to insert lengthy tables, and for the purposes of qualitative research 
the word cloud offers a more contextual interpretation of the data. 
Figure 3.2  
Siblings Word Cloud 
 
Figure 3.2 Siblings Word Cloud. [The word cloud illustrates autism, affected, children, 




Feelings represented the emotions, thoughts, and physical response related to 
autism reported through social media hits. This category contained 178 out of 1930 hits 
with 1936 coded references. The majority of hits was self- reports from caregivers or 
parents of individuals with autism; indicated by word counts that included child 
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(weighted percentage of 1.28% or 40 counts) or children (weighted percentage of 0.45% 
or 14 counts). Figure 3.3 is a word cloud produced from all the hits within the “feelings” 
category. 
Figure 3.3  
Feelings Word Cloud 
 
Figure 3.3 Feelings Word Cloud. [The word cloud shows the words autism, child, know, 
like, people, parents, and time are most frequently counted.]  
 
Many of the caregivers or parents expressed concern, frustrations, or reactions to 
the diagnosis and management of autism. One of the most important terms in the 
“feelings” category was to know which terms took on multiple meanings. The term 
“know” was mentioned 28 times for a weighted percentage of 0.90%, but it yielded many 
different meanings as shown in the paraphrased excerpts below:  
Caregivers or parents know what is best for his/her child 




I [individual with autism] can choose the best for myself because I want to be 
well.  
 
Call me an autistic person, but do not define me by my disease as a person with 
autism. I have a name so introduce me by my name so that people can know who 
I am. 
 
Nothing could be worse than watching my child in pain. My child bites, pinches, 
and hits his/her body to the point of bleeding, bruising, and swelling. 
 
The term “know” took on many different forms. First, the act of “knowing” from 
the perspective of a parent or caregiver, described understanding their child’s response to 
treatments or interventions. In many cases, the parent or caregiver identified the 
symptoms of autism first and then sought out an explanation. This suggests a need for an 
instrument to record home experiences and log response to interventions. Some parents 
make daily logs that record their child’s response to foods, medications, and therapies. 
These become valuable to help the clinicians manage the treatment of autism. This 
resource also points toward the importance of a strong relationship and communication 
between the caregiver, parent and the clinicians. In almost all cases the parent or 
caregiver fulfills the role of patient advocate.  
Secondly, the term “know” referred to understanding or wanting to know more 
about autism as a disease. Even though there is a plethora of information available on the 
internet regarding autism, parents or caregivers often question the reliability of the 
information. As pointed out in the “lack deficit needs” category, information from the 
internet can be contradictory in nature and not always scientifically based. It may be 
difficult for parents or caregivers to: (1) locate reliable and scientifically based 
information; (2) understand ASD because of the extensive use of scientific or clinical 
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jargon; and (3) comprehend the full meaning of the information due to the emotional and 
physical stress they are experiencing. Additionally, social media suggests that most 
parents want to know and understand their child(ren); which can be difficult due to 
problems with communication and isolation. Parents want to know what their child likes 
and does not like, and they want to know and understand their pain. From the data 
entries, several examples of communication devices or methods emerged as helpful tools 
in relaying messages between the individual with autism and other individuals. For 
example, sign language or picture boards were found to be useful in stimulating 
communication at home.  
 Another perspective mentioned in social media was that of the affected individual. 
The desire of the affected individuals to feel normal was present in social media entries. 
On a personal level, individuals with autism want to be treated equally with non-affected 
individuals on a personal level. They appreciated others treating them as normal not as 
different and including them in daily activities with other children their age or 
introducing them to new people without identifying their disease. This reinforces the 
stigma of having a mental disorder (Link & Phelan, 2013; Pescosolido, Medina, Martin, 
& Long, 2013; Szeto, Luong, & Dobson, 2013; Thoits, 2013). Individuals with autism 
desire respect as an individual and they want to be included in a discussion about the 
future interventions. According to this data, individuals with ASD want and should have 





People with autism see the same world in a different way 
Some of the strongest feelings represented in the contextual data are displayed in table 
3.2.  
Table 3.2  
Types of Feelings and Weighted Percentages  
Type of Feeling Weighted Percentage (%) 

























Table 3.2 Types of Feelings and Weighted Percentages.  
 
Many of the feelings either surround the initial reaction of diagnosis or the feeling is a 
reaction to demands and comments of society. The following is an example of a 
combined reaction that clearly expresses the feelings of the parent. 
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The doctor gave the diagnosis and I [the caregiver] became overwhelmed with 
fear, guilt, and extreme sadness. I was nauseated from the news… feeling like I 
had let my child down. I felt like it was fault and that my child’s future would be 
hindered by this diagnosis. It was the worst feeling in the world. Comforting and 
reassuring words were not accepted.  My gut feelings told me to seek a second 
opinion and reject this diagnosis. I refused to accept that autism is a permanent 
disorder and that nothing can be done. I tried to think of ways to keep my child 
from getting sick, ways to improve the current state, and ways to help others who 
are in the same situation. I immediately began to research autism. I read 
everything I could find related to healing Autism. 
 
My spouse was working multiple jobs to provide for our family. I stayed home 
with my children and worked from home. One of the hardest, darkest times in my 
life was learning of our child’s diagnosis of autism. No one seemed to 
understand… We heard all kinds of comments from people. Most of the things we 
heard were negative about our parenting or about our children. The comments 
made it seem like we had done something wrong- that this was our fault. I 
searched in desperation for an answer. We mourned the ideas and aspirations that 




Proposed links was defined as elements suspected to have a relationship with 
autism, but remain under scientific investigation. The items listed under this category 
produced much debate among respondents. Proposed links contained 1344 out of 1930 
















Figure 3.4  
 
Proposed Links Word Cloud 
 
 
Figure 3.4 Proposed Links Word Cloud. [The word cloud shows that symptoms, food, 
vaccines, gut, brain, and children were the most frequently counted words associated with 
proposed links with autism.]  
 
Interestingly, the raw data counts listed autism (536 counts or 7.79%), gut (82 
counts or 1.19%), vaccines (77 counts or 1.12%), and children (72 counts or 1.05%) as 
the top four words counted under the category of proposed links. Further evaluation of 
the word counts, revealed that 174 of 1344 counts contained terms synonymous with 
gastrointestinal function or location followed by terms for vaccines (143 counts) and 
children (98 counts). The coded hits suggest there is a relationship between the GI system 
and ASD. In this study, the majority of coded entries under gastrointestinal terms refer to 
symptoms related to autism or the GI system present during early years before diagnosis 
of autism. It is unclear from the data whether autism or GI symptoms occur first, or if a 
causal relationship exists.  
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Unlike the references coded for gastrointestinal, the majority of hits under 
vaccines stemmed from debate surrounding the well known and re-tracted article 
published in the Lancet by Wakefield et al (1998) and warning labels produced by 
vaccine manufacturers. For the purpose of this study, vaccines are acknowledged as a 
potential mechanism by which an individual can be exposed to bacteria or viruses which 
trigger a cascade of events that lead to diverse symptoms. However, these pathways 
require more scientific research to implicate them with the onset of autism (Tomljenovic, 
Blaylock, & Shaw, 2014).  
Family History of Individuals with ASD 
Family history accounted for 62 of 1930 hits with 1932 coded references. Family 
history was defined as self described symptoms, exposures, diseases, or events that 
occurred in the life of a person who indicates a relationship with an autistic proband. 
Mothers were the most frequently reported (18 counts or 1.82%) in relationship with the 
proband and among mothers pregnancy (15 counts or 1.51%) was most frequently 
discussed as having a possible connection to the affected individual. Autoimmune disease 
(7 counts or 0.71%, diabetes 3 counts or 0.30%), depression (6 counts or 0.61%), pain (6 
counts or 0.61%), gastrointestinal (bowel 5 counts or 0.50%, digestive 3 counts or 0.30%, 
celiac 3 counts or 0.30%, constipation 3 counts or 0.30%), allergies (4 counts or 0.40%), 
arthritis (4 counts or 0.40%), fibromyalgia (4 counts or 0.40%), and cancer (4 counts or 
0.40%) were most frequently reported diseases and symptoms reported in family history. 
Most of the discussion on family history was by families attempting to find an 
explanation as to why their child developed ASD.  
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Our family does not fit any genetic models of inheritance, since no one on either 
side of our families is autistic.  
The use of pitocin (6 counts or 0.61%) was the most frequently discussed medication 
listed in family history believed to result in a child with autism. One of the particular 
problems related to the use of pitocin was the cited “unregulated cap on the highest level 
of pitocin allowed.” A recent study by Gregory et al (2013) has found that the risk of 
having a child with autism increased with induction and augmented childbirth. Therefore, 
a complete pregnancy and birth history are critical.  
Figure 3.5  
Family History Word Cloud  
 
Figure 3.5 Family History Word Cloud. [Mother and family have the highest word counts 










Pathology identified 43 of 1930 hits (1931 coded references) with the most 
common pathology of autism being related to the gut (gut 12 counts or 1.78%, intestinal 
5 counts or 0.74%, digestion 4 counts or 0.59%, gastrointestinal 2 counts or 0.30%) or 
bacteria (8 counts or 1.19%) compared to genetic inheritance (DNA 4 counts or 0.59%, 
gene 2 counts or 0.30%, genes 3 counts or 0.45%, genetic 3 counts or 0.45%). The results 
suggest that social media participants believe genetics play a large role in the pathology 
of autism. The relationship between gastrointestinal genes and their relationship to autism 
appears to be strong based on pathology key words. Some examples of GI pathways 
mentioned in social media include the following: 
Failure of digestion that initiates a cascade leading to cognitive decline 
Mucosal surface damage of the gastrointestinal tract leading to immune 
suppression 
 
Genetic predispositions and environmental exposures leading to unhealthy gut 



















Figure 3.6  
 
Pathology Word Cloud  
 
 
Figure 3.6 Pathology Word Cloud. [Bacteria and gut are the most counted words 
associated with autism pathology.] 
Coping Mechanisms 
Coping mechanisms include 53 of 1930 hits with 1931 coded references. Coping 
mechanisms are defined as means by which families or individuals deal with problems 
and situations related to autism. The main way families and individuals cope with autism 
is through support systems. People (7 counts or 1.01%), kids or children (9 counts or 
1.30%), and parents (5 counts or 0.72%) are the top three terms representing support 
systems. A support system provides sharing (4 counts or 0.58%) and time (4 counts or 
0.58%) to help the families and individuals deal with their stresses related to autism. 
People also find resolve in things (5 counts or 0.72%), which most frequently includes 
some form of writing activity (writing 3 counts or 0.43%, Facebook 3 counts or 0.43%, 
blogging 2 counts or 0.29%). Paraphrased notes from social media hits indicate the 
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writing activity allows the people to share their lives, dispel myths about autism, and 
share what they have learned.  
Figure 3.7  
Coping Mechanisms Word Cloud 
 
Figure 3.7 Coping Mechanisms Word Cloud. [The highest ward counts for coping 
mechanisms are people, parents, kids, and things.]  
Consequences 
Consequences were defined as the result of or an effect of any action related to 
autism. There were 74 consequences out of 1930 hits with 1931 coded references. Most 
consequences effected children (children 9 counts or 1.27%, child 8 counts or 1.13%) or 
families as a whole (8 counts or 1.13%). Consequences resulted from the topic of 
vaccinations (13 counts or 1.82%), which was two sided. Those who received 
vaccinations most frequently reported side effects which lead to controversial belief that 
vaccines lead to autism. Secondly, the lack of vaccinations (4 counts or 0.56%) has 
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resulted in increased exposure, presence of diseases that could be prevented (e.g. measles 
0.84% or 6 counts) and life-threatening dangerous complications.   
Figure 3.8  
Consequences Word Cloud 
 
Figure 3.8 Consequences Word Cloud. [The highest word counts for consequences were 
children, family, child, people, measles, and vaccines.]  
No Link to Autism 
 There were 55 of 1930 hits that stated that there were no causative links with 
autism. Topping this list was vaccines (35 counts or 7.69%) which were clearly indicative 
of the retraction and lack of scientific evidence that vaccines cause autism. Celiac (8 
counts or 1.76%) was also included in this list due to recent publication that found no 





Figure 3.9  
No Link to Autism Word Cloud 
 
Figure 3.9 No Link to Autism Word Cloud. [Vaccines had the highest word count from 
the no link to autism category.] 
Lack Deficit Needs 
 The category of “lack deficit needs” is defined as resources related to autism that 
are absent, scarce, or insufficient to meet the needs. This category was made up of 188 of 
1930 hits with 1329 coded references. The category was further broken down into the 
following subcategories. 
Table 3.3  
Lack Deficit Needs Sub-Category References 
Sub-Category Number of Coded References 
Problems with medical interpretation 63 
Need for testing or treatment 43 
Cost 36 
Problems diagnosing 29 




Access to healthcare 18 
Parental interference 14 
Need for information 14 
Legal representation 11 
Access to specialized education 11 
Employment 5 
Abuse 4 
Lack of support 4 
Failure of prescription compliance 3 
Need for proper labeling 2 
Unapproved uses of treatment 2 
Failure of assistance program 1 
Missing person 1 
Table 3.3 Lack Deficit Needs Sub-Category References. [The numbers represent the 
coded references within the node.]  
 
The majority of complaints about gaps were focused on meeting the needs of 
children with autism, which included deficiencies in doctors (35 counts or 1.16%) and 
medical care (16 counts or 0.53%). Problems with pediatricians were noted specifically in 
the word count eight times. Of the deficiencies, misdiagnoses and costs or money topped 
the list, 0.23% (7 counts) and 0.23% (7 counts) respectively. Examples related to 
healthcare include problems with medical interpretation (coded 63 times), lack of testing 
or treatment (coded 43 times) and excessive cost of care (coded 36 times). The following 
are paraphrased entries from social media that capture these complaints: 
The medical approach to medicating individuals with autism relies on trial and 
error due to the lack of pharmacogenetic testing. Dosages are adjusted differently 
for each person, and one medication may be ineffective or have negative effects 
while others are helpful. 
 
Medical expenditures for individuals with ASD are very costly, reaching an 
average five times greater than those without ASD.  
 
Pediatricians are reluctant to diagnose ASD early.  
 




Health professionals lack training to deal with ASD. 
 
Figure 3.10  
 
Lack Deficit Needs Word Cloud 
 
Figure 3.10 Lack Deficit Needs Word Cloud. [The largest word counts for lack deficits 
and needs were children, child, symptoms, doctors, and medical.] 
Many complaints mentioned the use of a trial and error approach to treatment, and 
some hits even expressed a need for better education and training for healthcare 
professionals. Items in the “problems diagnosing” sub-category referred to the inability to 
distinguish autism symptoms from other diseases like attention deficit disorder, thyroid 
disorders, Lyme disease, Rett syndrome, and 22q13.3 deletion syndrome. Treatment 
failure focused on side effects, resistance, or tolerance of drugs.  
 Examining the sub-category of “employment” indicated ineffective interventions 
for autism made it difficult for these individuals to obtain and keep employment. The 
sub-category of “employment” showed 100% negative outcomes for employment of 
autistic individuals so it was moved from abilities to the lack deficit need category. All of 
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the coded references expressed problems in holding a job citing “numerous terminations” 
from “being too sensitive to having difficulty concentrating.” 
 Sub-categories of abuse, lack of support, parental interference, and failure of 
compliance or from assistance programs help explain from where problems emerge. 
Failure of compliance refers to care givers, parents, or autistic individual’s adherence to 
prescribed treatment programs either with medication, diet, or therapies. Parents express 
difficulty in forcing children with food aversions or sensitivities to take medicines or 
maintain diets. Several ways were offered throughout the data to resolve this problem: 
mixing medicine in foods, making the medicines available in different forms (i.e. tablets, 
liquids, sub lingual forms, or by injections), or pharmacogenetic testing to prevent trial 
and error.  
Parental interference occurred when parents or caregivers did not see response in 
their child or they saw adverse events in response to intervention methods. In some cases 
the caretaker failed to see the symptoms or regression, which led to delayed exposure or 
changes in intervention. In other instances, the caretaker failed to see an improvement 
and would seek out new interventions or add supplemental or unapproved interventions 
to care for their child. Feelings of denial and desire to give the child the best can fuel 
parental actions and create counter effects from what is intended. The following are 
summarized excerpts that describe the extent of parents over reacting and interfering in 
their child’s treatment. 




The parent or caregiver refuses to take his/her child back to the pediatrician 
because of a statement made stereotyping parents of ASD children wanting a 
diagnosis for financial assistance.  
Some parents try to please their child with ASD so much that the child can get 
away with anything. In extreme cases the child completely rules the house with no 
parental control.  
The parents refused to have their child evaluated for ASD at a young age because 
they felt the child’s symptoms were minimal. 
An individual with ASD wants to feel independent and gain respect from his/her 
parents.  
Age at Onset 
The age of onset was defined as the self-reported age at which the parent or 
caregiver noticed symptoms that were non-typical leading up to a diagnosis of autism. 
The age of onset category was made up of 61 out of 1930 hits with 1283 references. The 
category was subcategorized to capture the age of onset at birth (18%), 12 months or less 
(39.3%), 24 months or less (31.1%), and 36 months or less (6.6%).  
Age at Diagnosis 
The age of diagnosis was self-reported in 44 of 1930 hits with 540 coded 
references. The age of diagnosis was sub-categorized into age in years at diagnosis.  
Table 3.4  
Age at Diagnosis Sub-categorization into Years 
Age in Years Number of References Coded for Age 
1 year or less 10 
2 years 12 
3 years 11 
4 years 5 
6 years  1 
7 years 2 
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8 years 0 
9 years 1 
10+ years 3 
Table 3.4 Age at Diagnosis Sub-categorization into Years. 
 
The youngest individual diagnosed with autism was five months of age and the oldest 
was 17 years of age. Most frequently children were diagnosed around one year of age.   
Figures 3.11 and 3.12 illustrate age of onset and age of diagnosis. A gap is visible 
between age of onset around 12 months and age of diagnosis at two years. 
Figure 3.11 
 



































Figure 3.12 Autism Age of Diagnosis 
Interventions 
The category labeled interventions contained 878 of 1930 hits with 1260 
references. Interventions were defined as something that occurs between two points in 
time as related to autism. The word count summary identifies diet (164 counts or 1.65%), 
therapy (123 counts or 1.23%), and gluten (59 counts or 0.59%) to be the top three ways 
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Autism Age of Diagnosis 
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Figure 3.13  
Interventions Word Cloud 
 
Figure 3.13 Interventions Word Cloud. [The words with the highest count included diet, 
therapy, child, children, gluten, food, and supplements.]  
Interventions were sub-categorized as “actions”, “supplements”, “diet”, 
“therapies”, “medications”, “support”, “specialists”, “medical testing”, “education”, 
“tools”, “devices”, “warnings”, or “treatment resistance”. The most common “action” 
was early intervention, which seemed to lead to better outcomes through the disease 
process. The following are some paraphrased examples from the social media hits:  
Early detection of ASD can protect caregivers, parents, and affected individuals 
from severe consequences  
Young children respond faster to interventions than older children, which improve 
their quality of life long term.   
Of course, early intervention could not be achieved without helps from other resources or 
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combined actions.  
From the sub-category of actions, “helps” were counted 24 times (0.60% 
weighted percentage) as the most important term used to define action. Examples of help 
include:  
helping an individual with ASD with reading and language 
helping an individual with ASD re-learn important cues 
helping the public understand autism 
helping promote studies on gene-environment interaction  
Other terms synonymous with help were also indicated as actions of importance such as 
advocate or give. Much of the action listed in the entries was two-folded focusing on 
learning, gaining knowledge, or relaying positive messages either for the caregiver, 
family, or affected individual. In either situation the one acting to provide an intervention 
would also gain from his/her actions through personal growth.  
For the individual with autism, one of the themes seen under this category 
referred to learning or obtainment of skills. Life skills are important to the person in 
overcoming developmental delays, obtaining employment, learning, and being able to 
function with everyday tasks. One post in social media discussed the impact of life skills 
on the individual sharing that experience and coping skills empower students to solve 
problems and recognize stress levels. As with any form of intervention, support is needed 
to obtain and maintain the resources to make a difference in the disease processes.  
Support is another sub-category of interventions containing 119 coded references. 
Support is dependent on the actions of many individuals. The word count shows that 
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support is influenced most by support groups (3.12%), family (1.40%), books (1.25%), 
parents (2.18%), community (0.78%), Facebook (0.47%), and friends (0.47%). Although 
specialists were sub-coded separately, they need to be included to provide medical 
support and guidance toward treatment options. The most sought after types of specialists 
were: chiropractors (3.72%), developmental pediatricians (3.10%), and neurologists 
(1.86%). This number was heavily influenced by the increased number of social media 
entries by chiropractors versus other medical specialists.  
It was apparent, within social media, that parents and caregivers have sought out 
unconventional treatments for their children due to deficits in healthcare and failure of 
treatments. Many of these unconventional treatments utilize complementary or alternative 
treatments (Akins et al., 2014). Supplements (288 references) or diets (281 references). 
Oil (3.0%), magnesium (1.64%), vitamins (4.09%), enzymes (1.45%), glutathione 
(1.45%), and amino acids (1.09%) were the most frequently mentioned forms of 
supplements. Several dietary changes were reported as effective in reducing symptoms 
related to autism. These diets included elimination of gluten, casein, dairy, and/or sugar. 
Elimination of these four items either individually or in some combination made up 125 
hits. Many people had self-reported success with the Gut and Psychology Syndrome 
(GAPS) nutritional program (2.52%), commonly referred to as the GAPS diet, which is a 
combination of diet, supplementation, and detoxification. Other diets of mention were 
organic (1.03%), fermented foods (0.84%), and ketogenic diets (0.84%). Usually, the 
incorporation of diet and therapy was seen as beneficial in treating symptoms of autism. 
Therapeutic measures and medications differed based on the severity and 
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symptoms manifested in the individual. Speech (3.93%), behavioral (2.62%), 
occupational (2.62%), chelation (1.31%), sensory (1.16%), biomedical (1.02%), music 
(1.02%), physical (1.02%), play (1.02%), and stem cell therapies (1.02%) were just a few 
of the therapies mentioned in social media. Much emphasis was placed on the success of 
applied behavioral analysis (2.62%), which is a comprehensive form of therapy that 
focuses on modifying behaviors. Although therapy alone can positively impact 
behavioral patterns, sometimes the presence of co-morbid diseases or severity of autism 
symptoms requires the use of medications as coded in 135 references. Medications most 
frequently used by autistic individuals include antibiotics (4.15%), marijuana (3.9%), 
Miralax (1.95%), Diflucan (1.22%), Risperdal (1.22%), Ritalin (1.22%), Nystatin 
(0.98%), and antidepressants (0.98%). Of course medications used are linked with 
symptoms.  
While devices made up only 30 of the 1260 references for interventions, posts 
demonstrated a need for more integration based on the positive outcomes that have 
resulted from their use. Communication (6.14%) was the number one use for devices, 
such as iPads (7.89%), computers (2.63%), and special lenses (2.63%). Software 
applications were discussed due to their personalization to the user’s needs. Integrated 
devices in healthcare were of benefit to the clinicians as well. One example from social 
media described how computer automation helps pediatricians focus on the individual 
and the personalized needs of each patient.  
Devices were also supportive in emergency situations. One example of this 
described in social media is the development of a communication book designed for first 
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responders that is valuable when a person cannot verbalize how they feel. It is evident 
from the posts on social media that devices help improve symptoms and provide 
important ways to communicate in general and in emergency situations. The use of such 
devices support a child’s education, medical care, and monitoring of patient’s needs 
related to personalized medicine. Devices bridge the gap between treatment and 
symptoms by making the symptoms more apparent through day to day records and 
allowing treatment responses to be monitored more easily.  
Symptoms 
In this study, “symptoms” included a wide range of physical or mental 
appearance, reaction, and diagnosed diseases or disorders that are apparent in individuals 
who also have a self-reported diagnosis of autism. The symptoms in the data were 
defined in both lay and medical terms and with or without supportive laboratory results, 
demographic or family history information. From social media, 692 of 1930 hits were 
coded under “symptoms”, which were further divided into sub-categories. 
Table 3.5  
 
Sub-Categories of Symptoms 








Mental processes 130 
Feeding Problems 105 
Pain 97 




Laboratory Levels 80 
Immune System 71 
Skin 62  
Respiratory 59 
Delayed Development 48 
Genetics 45 
Nutritional Deficiency 37 
Vision 30 
Ear Nose Head 29 
Inflammation 29 
Ambulation 29 
Adverse Reactions 25 
Height and Weight 24 
Muscles 23 
Relationships 20 







Limbs and Joints 12 




Progression with Age 7 
Jaundice 6 
Failure to Thrive 6 
Bone 5 




Reproductive Organs 3 
Death 3 
Frequency of Illness 2 
Liver 1 
Table 3.5 Sub-Categories of Symptoms.  
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Behaviors, gastrointestinal, and communication problems covered 71.1, 69.6, and 
47.5% respectively, of the symptoms identified in social media. The word cloud for 
symptoms specified the problems associated with autism even further.  
Figure 3.14  
Symptoms Word Cloud 
 
Figure 3.14 Symptoms Word Cloud showing increased word counts of constipation, food, 
diarrhea, allergies, and general problems with autism.  
 
Food allergies (138 counts or a weighted percentage of 1.19%), constipation (122 counts 
or 1.05%), diarrhea (97 counts or 0.84%), and pain (79 counts or 0.68%) were the most 
frequently used words to describe symptoms. For gastrointestinal problems alone 
constipation, diarrhea, and reflux were the main symptoms seen in autism patients.  
Questions 
 
 The questions category included 122 of 1930 hits with 820 coded references. This 
category was sub-categorized into questioning causes and links, clinicians, ethics, 
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information, insurance, and interventions. Many of the questions focused on legitimacy 
of treatments, safety, and sought to find information from others who have experienced 
similar situations. Questions asking for definitions of autism were left unanswered by the 
respondents.  
Other emphasis was placed on the role that parents and caregivers should take by 
questioning diagnoses and suggested intervention methods, leaving a heavy weight of 
skepticism among the autistic community. It is evident from the posts that people are 
seeking answers, and expectations are high for legal representatives, organizations, and 
government agencies to respond. The following are paraphrased excerpts from social 
media hits that express the questions being raised: 
Why do we see increases in cancer, autism, and allergies but human DNA 
sequences have not changed at all? 
How does a parent know if their child with ASD has leaky gut syndrome? 
 
Why, doctor, is this happening to my child?   
 
Which risk outweighs the other: the chance that a child will be autistic from 
vaccination, or the chance that a child will die from a disease that could be 
prevented? 
 
What should society do if the prevalence of ASD is not enough to get government 
to fund research or programs for those with autism? 
 












Figure 3.15  
 
Questions Word Cloud 
 
Figure 3.15 Questions Word Cloud showing increased word counts of questioning 




Improvements were defined as reductions in symptoms as a result of intervention. 
The self-report from social media resulted in 75 of 1930 hits with 787 coded references. 
Improvements were sub-categorized into allergy reduction, behavior improvements, 
communication improvements, dermatological improvements, endocrine improvements, 
gastrointestinal improvements, growth improvements, hearing, infections, insurance 
coverage, medication, neurological, nutrition, parenting, personal care, reduced adverse 
events, reduced inflammation, renal improvements, sleep patterns, toilet training. The 
overall word count for improvements indicates that there are less symptoms (8 counts or 
1.08%) which include behavior (7 counts or 0.95%), language or speech (14 counts or 
1.9%), cognition (5 counts or 0.68%), contact (5 counts or 0.68%), eye (5 counts or 
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0.68%), focus (5 counts or 0.68%), school (5 counts or 0.68%), and skills (5 counts or 
0.68%).  
Figure 3.16  
Improvements Word Cloud 
 
Figure 3.16 Improvements Word Cloud illustrates increased word counts of 
improvements in symptoms, behavior, language, speech, and diet. 
 
Out of the word lists of improvements, diet is counted 7 times with a weighted percentage 
of 0.95%, suggesting that it has a strong relationship with improved outcomes. From the 
sub-coding, neurological improvements had 41 coded references, communication 38 
coded references, behavior 27 coded references, and gastrointestinal 10 coded references 
of specific examples of improvements from interventions. Out of all the improvements, 
no one intervention had the same effect among the individuals with autism. Positive 
response to treatment was best achieved when issued on a personal level. Unfortunately, 
in all cases the improvements were not seen until after much trial and error. Without 
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going into symptoms and interventions which have been discussed earlier, the following 
are some paraphrased examples of improvement that was commonly seen throughout 
social media.  
Our child is doing great and is more engaged. He/she is talking and socializing 
more. 
 
Our child has a better skin color, weighs more, is taller, and has a healthy 
appetite. The ear infections and chronic diarrhea are gone, and the thyroid has 
normalized. We see much improvement in his/her behavior and school work. 
 
We have noted improvements in learning, socializing, focusing, eating habits, 
productivity, awareness, speech, attention, counting, labeling, following 
directions, eye contact, and understanding non-verbal communication. 
Additionally, we have seen a developing interest in others, better adaptation with 
change, and having a natural curiosity about the world. 
 
We placed our child with ASD on biomedical therapy. After several months of 
therapy, she/he was evaluated by a group of independent professionals who had 
never met him/her before. The speech and occupational therapists could not detect 
ASD in our child. When the laboratory reports came back normal the biomedical 
therapist said we no longer needed their services. 
When implementing a diet, one rather unique method for families to offer 
treatment and show support was for the entire family to follow the nutritional plan. In 
some instances, siblings also showed improvement in acting out, learning, and reduction 
in their own symptoms related to a disease other than autism, such as attention deficit 
disorder or allergies.  
Abilities 
Abilities are defined in this study as the possession of skills or talents that the 
individual with autism displays. Out of 1930 hits only 18 defined specific abilities. The 
most common passions focused on music (7 counts or 9.23%), math (3 counts or 3.95%), 
and art (2 counts or 2.63%). Other areas of interest included sewing, dance, computers, 
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science, and horses. One theme defined through the posts was developing and utilizing an 
individual’s special abilities to make them self sustainable. For example, organizations 
exist that assist individuals in obtaining skills, improving their lifestyle, and providing 
them with future employment by taking their interests such as art to create practical 
commodities.  
Figure 3.17  
Abilities Word Cloud 
 
Figure 3.17 Abilities Word Cloud shows the largest word counts were skills, math, 




Cluster analysis was performed in NVivo to group together nodes based on words 
in common. All nodes were selected and clustered by word similarity using a Pearson 
correlation coefficient similarity metric. A Pearson correlation close to -1 indicates the 
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items are not similar, and a Pearson correlation close to +1 shows the items are more 
similar to each other. The following is a diagram of nodes clustered by word similarity: 
Figure 3.18  
Nodes Clustered by Word Similarity 
 
Figure 3.18 Nodes Clustered by Word Similarity produced by QSR NVivo 10. 
Table 3.6  
Pearson Correlation Between Nodes 
Node A Node B 
Pearson correlation 
coefficient 
Questions Proposed Links 0.8185 
Proposed Links No Link to Autism 0.8120 
Questions Lack Deficit Need 0.7532 
Lack Deficit Need Feelings 0.7121 
Proposed Links Lack Deficit Need 0.7001 
Questions No Link to Autism 0.6958 
Questions Feelings 0.6635 
Lack Deficit Need Intervention 0.6238 
Questions Intervention 0.6057 
No Link to Autism Lack Deficit Need 0.5991 




Lack Deficit Need Consequences 0.5693 
Proposed Links Feelings 0.5630 
Questions Consequences 0.5581 
Feelings Consequences 0.5556 
Proposed Links Consequences 0.5523 
Proposed Links Intervention 0.5402 
Lack Deficit Need Coping 
Mechanisms 
0.5357 
Proposed Links Pathology 0.5169 
Intervention Feelings 0.5154 
No Link to Autism Consequences 0.4890 
Questions Family History 0.4825 




Siblings Lack Deficit Need 0.4764 
Siblings Questions 0.4754 
Feelings Family History 0.4731 
Siblings Proposed Links 0.4645 
Intervention Consequences 0.4631 
Proposed Links Family History 0.4596 




No Link to Autism Intervention 0.4343 




Symptoms Questions 0.4152 
Symptoms Proposed Links 0.4135 
Siblings Feelings 0.4123 
Symptoms Lack Deficit Need 0.3997 
Intervention Improvements 0.3978 
Siblings No Link to Autism 0.3952 
Proposed Links Coping 
Mechanisms 
0.3952 
Questions Pathology 0.3918 
Symptoms Intervention 0.3912 
Lack Deficit Need Improvements 0.3793 
No Link to Autism Family History 0.3728 
Symptoms Feelings 0.3706 
Symptoms Family History 0.3694 
Intervention Family History 0.3636 
Symptoms Improvements 0.3567 




Siblings Consequences 0.3490 
Age at Onset Age at Diagnosis 0.3473 
Siblings Intervention 0.3446 
Questions Improvements 0.3374 
Pathology No Link to Autism 0.3355 
Siblings Family History 0.3340 
Family History Coping 
Mechanisms 
0.3300 
Proposed Links Improvements 0.3279 
Pathology Lack Deficit Need 0.3261 
Symptoms Consequences 0.3201 
Symptoms Pathology 0.3159 
Improvements Feelings 0.3136 
Siblings Age at Onset 0.3129 




Symptoms Age at Onset 0.2945 
Pathology Feelings 0.2906 




Improvements Consequences 0.2803 
Lack Deficit Need Age at Onset 0.2753 
Pathology Family History 0.2723 
Siblings Age at Diagnosis 0.2685 
No Link to Autism Improvements 0.2571 
Improvements Family History 0.2495 
Proposed Links Age at Onset 0.2445 
Symptoms No Link to Autism 0.2444 
Family History Age at Onset 0.2378 
Consequences Age at Onset 0.2359 
Siblings Pathology 0.2298 
Siblings Improvements 0.2284 




Improvements Age at Onset 0.2168 
Symptoms Siblings 0.2156 




Intervention Age at Onset 0.1985 
Pathology Improvements 0.1781 





Age at Onset 0.1512 
Pathology Age at Onset 0.1503 
Lack Deficit Need Age at Diagnosis 0.1393 
Questions Age at Diagnosis 0.1151 
Family History Age at Diagnosis 0.1117 
Proposed Links Age at Diagnosis 0.0978 
Consequences Age at Diagnosis 0.0937 
Feelings Age at Diagnosis 0.0902 
Symptoms Age at Diagnosis 0.0873 
Coping 
Mechanisms 
Age at Diagnosis 0.0858 
Intervention Age at Diagnosis 0.0835 
No Link to Autism Age at Diagnosis 0.0767 
Improvements Age at Diagnosis 0.0732 
Symptoms Special Abilities 0.0669 
Media Provider Coping 
Mechanisms 
0.0577 
Special Abilities Improvements 0.0554 
Special Abilities Intervention 0.0488 
Special Abilities Coping 
Mechanisms 
0.0416 
Pathology Age at Diagnosis 0.0345 
Special Abilities Feelings 0.0272 
Special Abilities Age at Onset 0.0268 
Special Abilities Consequences 0.0262 
Media Provider Feelings 0.0196 
Special Abilities Family History 0.0090 
Special Abilities Pathology 0.0079 
Special Abilities Lack Deficit Need 0.0070 
Special Abilities No Link to Autism 0.0059 
Special Abilities Questions 0.0011 
Special Abilities Proposed Links 0.0007 
Media Provider Intervention -0.0010 
Media Provider Age at Diagnosis -0.0017 
Siblings Media Provider -0.0020 
Media Provider Lack Deficit Need -0.0021 
No Link to Autism Media Provider -0.0021 
Special Abilities Media Provider -0.0021 
Media Provider Age at Onset -0.0031 
Proposed Links Media Provider -0.0032 
Pathology Media Provider -0.0039 
Media Provider Improvements -0.0039 
Questions Media Provider -0.0045 
Special Abilities Age at Diagnosis -0.0047 
Media Provider Consequences -0.0053 
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Media Provider Family History -0.0055 
Special Abilities Siblings -0.0056 
Symptoms Media Provider -0.0065 
Table 3.6 Pearson Correlation between Nodes depicted as decreasing Pearson Coefficient 
values. 
 
Cluster analysis between sub-categories of questions and proposed links indicates 
a high positive correlation between questioning causes and links and proposed links 
(r=0.8572), proposed links and no link to autism (r= 0.811967), and questions and lack 
deficit need (r= 0.7532).  
Discussion 
Analysis of social media entries for autism identified patterns and themes related 
to GI symptoms. A pattern of symptoms leading to a diagnosis of autism included 
infection at a young age, appearance of altered bowel function (e.g. constipation, 
diarrhea), increased behavioral problems, and diagnosis of ASD at least a year or two 
after onset. From the data, onset appears after birth and before 12 months of age. 
However, autism is often not diagnosed until two or three years of age which leads to 
frustration and skepticism for the current healthcare system. A need for early diagnostic 
testing is seen as desirable by parents, caretakers, and clinicians as long as it is effective 
and is accompanied by financial assistance. Types of financial assistance were identified 
in the data set as insurance, reimbursements, or tax deduction. Early diagnostics of 
particular interest, from the data, included tests that do not directly diagnose autism as a 
disease, such as pharmacogenetic testing and allergy testing. These tests provide direction 
in intervention application and monitoring. Patterns within the data also indicate 
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pathways of interest that would lead to development of such tests and earlier diagnosis of 
autism.  
Based on word counts and reoccurring self-reports of symptoms, the pathway 
identified in the data starts with an infection before twelve months of age. Infection is 
followed by or accompanied with bowel abnormalities which over time result in 
behavioral changes and increased co-morbid symptoms. The diagnosis of autism follows 
this progression years later.  
Three major themes emerge from the data: (1) proposed links to autism; (2) 
symptoms related to food allergies and GI issues; and (3) interventions. Proposed links to 
autism make up the largest theme found in social media. The links offer a glimpse into 
what are believed to be causative suggestions for ASD. The majority of participants in 
social media search for causes and answers related to ASD. In many cases one participant 
will share symptoms of ASD to either communicate with others experiencing the same 
symptoms or to seek advice for successful interventions. With no specific medication to 
treat ASD, parents and clinicians typically try different approaches to relieve symptoms.  
In the categories of proposed links, family history, pathology, and symptoms the 
gut or gastrointestinal tract is one of the most frequently used words; indicating a 
relationship between the gut and autism. Dietary measures and therapy (e.g. physical, 
occupational, behavioral, etc.) are the most commonly used interventions mentioned in 
social media. The data suggests that with a comprehensive family history, log of 
symptoms and reactions, and genetic information, a personalized treatment plan may be 
applicable to ASD. It also suggests a need to study multivariate patterns of inheritance as 
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related to GI disorders, autoimmune diseases, and allergies. Epigenetic and 
pharmacogenetic testing is also identified beneficial in the treatment and understanding 
of ASD. The extensive amount of trial and error that occurs during the treatment process 
suggest that implementation of pharmacogenetic testing may improve quality of life and 
lead to more direct positive outcomes.  
While social media offers many perspectives on autism which may be beneficial, 
it must be recognized that the software used to mine and analyze the data and the research 
team are limited in their abilities. Radian6 collected a wealth of data using the parameters 
identified, but it was limited in its ability to identify repeated entries or false leads in the 
data series. This resulted in the research team manually coding each entry and eliminating 
repeated posts and entries not related to the search criteria. Due to the size of the dataset 
and extensive time required to manually code the information, inexperienced research 
team members were not able to tolerate the research load along with their academic 
obligations. Therefore, the analysis from only one coder may present bias in the results 
and lend itself to lack of inter and intra reproducibility of the study. To reduce the effect 
of researcher bias, all the coded entries were uploaded into NVivo and an auto-code was 
performed based on the selected nodes. The entries were then sub-categorized and re-
coded if needed in NVivo. For future studies, it would be beneficial to develop a tool 
compatible with Radian6 and NVivo that would tag repeated entries and perform a 
secondary scan of the data for search criteria requirements. It would also be 
recommended to have at least three people to code the data to ensure interrater reliability 
or agreement among the results without bias.  
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Several factors presented as limitations to this study which could be improved in 
future research designs. First, the study lacks inter rater reproducibility due to the issues 
with coder retention. Future studies should seek funding to offer incentives and hire 
experienced qualitative research coders in order to prevent coders from dropping out of 
the research project. Second, the search terms entered into Radian6 produced an 
extensive amount of false leads which had to be removed manually. The results from 
Radian6 in addition to the use of manual coding increased risks of error. The 
development of syntax to identify repeated entries would reduce the number of false 
leads. Also, identification of specific search terms and the way in which they are entered 
into Radian6 may reduce the need for manual coding. One suggestion would be to test 
combinations of search terms and entry methods over a few days to determine the best fit 
model for a larger study. The data set could also be statistically analyzed using pathway 
modeling to determine if certain symptoms or categories could be used to model ASD 
using social media. Future studies could then focus on using social media to model other 
forms of disease and interventions.  
Several advantages exist for using social media data posted in the public domain. 
The first advantage is that it does not remove the person who providing the information 
from their typical environment. Social media preserves the data in its original context. 
Posts in the public domain reduce harm due to confidentiality breaches. It is assumed that 
when a person posts information in the public domain it is intended for the public to view 
and interpret on an individual basis. Information posted in the public domain allows equal 
access to anyone who wishes to analyze it, and it gives the research subject the 
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opportunity to regulate which information they wish to share and what they do not want 
to share.   
Conclusions 
Mining social media data provides a tool for translating experiences, symptoms, 
and reactions of disease into applicable categories that may be further studied as new 
pathways, interventions, or approaches to the disease. The purpose of this study was to 
explore social media in order to identify patterns and themes related to autism and GI 
symptoms. Eighteen categories emerged from the data set; the top three categories 
yielding themes of proposed links to autism, symptoms related to food allergies and GI 
issues, and interventions. The self-reported symptoms and pathology in social media 
indicate a pattern of infection at a young age that leads to GI symptoms and continues to 
progress, leading to layers of symptoms and eventually an autism diagnosis.  
Previous studies have identified associations between constipation, behavioral 
problems and ASD (Ibrahim et al., 2009; Kral et al., 2013). This study supports the 
previous associations through increased word counts for GI symptoms, behavior 
problems, and autism. Major complaints of GI symptoms included changes in bowel 
behavior and constipation after an infection at a young age. The pathology represented by 
the data of a pathogen interrupting the epithelial barrier and creating a cascade of 
symptoms is suggestive of the proposed gut to brain pathway. The data shows that layers 




Social media data gives individuals with autism a voice and it provides direction 
for future research and intervention. This research shows that social media data can 
identify suspected pathways of disease through identification of commonly reported 
symptoms, onset, and progression over time. Social media provides an excellent 
opportunity for participants to log experiences of disease over time and record treatment 
responses. Examples shared through personal experiences can benefit families to 
recognize symptoms and successful treatment options. Social media gives individuals and 
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Zonulin is a precursor for the protein haptoglobin 2 and functions to regulate epithelial 
tight junctions. Modulation of the tight junctions allows macromolecules to pass into the 
blood stream, causing a disruption in homeostatic mechanisms that play important roles 
in the development of immunity and disease. Symptoms related to epithelial barrier 
permeation have been correlated with autoimmune diseases and cancer, but there is 
reason to believe that similar gastrointestinal and neurological symptoms may be seen in 
persons with autism spectrum disorder (ASD). This study aims to determine if increased 
zonulin levels or haptoglobin genotypes are directly associated with ASDs among three 
groups: individuals diagnosed with ASD and gastrointestinal symptoms, newborns, and 
healthy controls. Results indicate a low negative correlation exists between zonulin 
concentrations and the three groups in addition to the haptoglobin genotypes and the 
groups. More studies are recommended to explain the presence of zonulin in 10% of ASD 
individuals and 20% of newborns compared to the lack of zonulin in the control group.  
Keywords: autism, zonulin, intestinal permeability, haptoglobin, newborns 
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Zonulin, pre- haptogolobin 2 (pre-HP2), is a complex protein structure that 
regulates epithelial tight junctions, allowing macromolecules to pass into the blood 
stream causing altered immune responses (Tripathi et al., 2009; Wang et al., 2000). 
Enterocytes of the small intestine release zonulin into the lumen when triggered by 
bacteria, parasites, or gliadin (Fasano, 2012). Zonulin exists in two forms: an un-cleaved 
form known as pre-HP2 that binds to protease activated receptor 2 (PAR2) and epithelial 
growth factor receptor (EGFR). The second form is cleaved by trypsin at Arg161 to form 
either an -2 or ß subunit of haptoglobin (HP) that seeks to bind hemoglobin but is 
unable to bind to EGFR (Fasano, 2012; Tripathi et al., 2009). Original studies indicate 
that the two different forms of zonulin yield two different functions due to the folding of 
the protein, with only the un-cleaved form affecting intestinal epithelial permeability 
(Fasano, 2012; Tripathi et al., 2009). Current research suggests that both forms of 
zonulin affect permeability, but the association between zonulin and autism spectrum 
disorder (ASD) is not known (Rittirsch et al., 2013). 
A literature search was conducted in PubMed using the search terms “zonulin,” 
“intestinal permeability,” “pre-haptoglobin 2,” and “epithelial permeability” from 2000-
2014. The results yielded 11060 publications. The search criteria was then refined to 
include autism using the search terms “intestinal permeability AND autism,” “zonulin 
AND autism,” and “pre-haptoglobin 2.” The results found 96 articles from 2000-2014. 
Article titles and abstracts were screened for inclusion of individuals with ASD, 
eliminating articles focused on animal studies, drug development, and emphasis on 
other developmental diseases.  
It is known that intestinal permeability is present in individuals with ASD. 
Lactose mannitol testing by D’Eufemia et al (1996) and De Magistris et al. (2010) have 
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identified intestinal permeability in ASD individuals at 43% and 36.7% respectively. 
Furthermore, the correlation between zonulin levels and severity of autism is supported 
by the results from Adams et al. (2011) that show children with more severe forms of 
ASD are likely to have more severe gastrointestinal (GI) symptoms. Children with higher 
Autism Treatment Evaluation Checklist scores had GI severity index scores greater than 
3 (p=0.00002) and lower levels of total short chain fatty acids (Adams et al., 2011). A 
large registry-based study of 589 individuals by Wang, Tancredi, and Thomas (2011) 
reported 42% of children with ASD had GI problems including constipation and diarrhea 
compared with their unaffected siblings (12%). Additionally, a more recent meta-analysis 
from research studies in peer-reviewed journals shows that GI symptoms of diarrhea, 
constipation, and abdominal pain are greater in children with ASD compared to children 
in control groups (McElhanon, McCracken, Karpen, & Sharp, 2014). 
Without measuring zonulin specifically, protein marker and genotyping 
exploration in individuals with ASD has indicated significant concentration differences 
in proteins related to zonulin. Of greatest interest are studies surrounding HP, a form of 
zonulin cleaved by trypsin and mapped to chromosome 16 (Fasano, 2011; Fasano, 2012; 
Swanwick et al., 2011; Tripathi et al., 2009). Aposhian et al., (2006) showed that HP 
plasma concentration was decreased in autistic male children (29.5±7.0 SE mg/dL) in 
comparison to healthy controls (91.8±14.8SE mg/dL, p=0.001). Additionally, Aposhian 
et al. (2006) identified an increase in HP2-2 genotypes in males with ASD (75%) 
compared to normal controls (40%). These results indicate that further testing is needed 
to determine relationships between HP and zonulin concentrations in serum, as well as 
relationships between protein concentrations and genotype. It may be possible that 
serum concentrations of HP are decreased due to decreased cleavage of zonulin, which 
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would indicate an increase in zonulin in the pre-HP2 form. Therefore, the central 
hypothesis of this research project is that increases in zonulin concentrations of serum 
are directly associated with ASD severity and that HP2-2 genotypes place an individual 
at a higher risk for developing ASD. 
Symptoms reported in ASD individuals implicate physiological mechanisms of 
zonulin in the onset of the disease. Symptoms of ASD include social impairment, 
communication difficulties, and repetitive and stereotyped behaviors; however, 
additional symptoms have been reported of stomach pain, diarrhea, constipation, acid 
reflux, vomiting, bloating, and food allergies (U.S. Department of Health and Human 
Services, National Institutes of Health, 2011). A review of the literature provides a list of 
diseases that show association between intestinal permeability and the zonulin pathway. 
Table 4.1 summarizes a list of these physiological pathways associated with zonulin and 
known disease states.  
[Insert Table 4.1] 
 
The literature identifies five physiological systems that are disrupted due to increased 
epithelial permeability: GI, Neurological, Oncology, Endocrine, and Respiratory 
Systems. Diseases associated with increased levels of zonulin have been suggested to be 
auto-immune, but there is reason to believe that symptoms related to increased zonulin 
levels may be seen in other diseases not yet classified as such. This dissertation research 
broadens the investigation to look at relationships between ASD, HP genotypes, and 
quantitative zonulin levels through the following aims:  
1. Determine if zonulin levels in plasma obtained from individuals diagnosed with 
an ASD (Group 1) or newborns (Group 2) are different from zonulin levels in 
controls of healthy individuals matched by age and/ or gender (Group 3).  
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2. Examine relationships between HP2 genotypes and increased zonulin 
levels in individuals with ASD (Group 1) or newborns (Group 2) 
compared to healthy controls matched by age and/or gender (Group 3).  
3. Determine if zonulin levels are good predictors between ASD and healthy control 
groups. 
Methodology 
 A non-experimental cohort comparison design of banked, convenience plasma 
sample and matching genomic deoxyribonucleic acid (gDNA) sample from the 
Greenwood Genetic Center was used in this dissertation study. Enrollment consisted of 
three groups: Group 1- individuals ages 6-15 years with ASD (n=10), Group 2- newborns 
(n=10), and Group 3- healthy gender and age matched controls to the autism group 
(n=10). The number of samples collected for the study was based on the Clinical 
Laboratory Improvement Amendments 88’ standards for clinical validation studies and 
the volume of samples obtained by the Greenwood Genetic Center on an annual basis. A 
minimum of 200uL of banked plasma and matching 20uL of gDNA was available for 
each group. Each sample was previously characterized through medical history and 
genetic testing to confirm the diagnosis of ASD. The healthy controls were also obtained 
from the Greenwood Genetic Center collection. These healthy controls were previously 
established as negative for ASD through medical history and genetic testing. All samples 
and data were identified only by laboratory accession numbers.  
 Inclusion criterion for diagnosed ASD individuals included a confirmed diagnosis 
of ASD as defined by the Diagnostic and Statistical Manual of Mental Disorders-IV 
(DSM-IV) criteria (American Psychiatric Association, 2013). Although the DSM has been 
updated to version V, the banked samples were collected under the DSM-IV criteria and 
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were measured by Autism Rating Scales developed under the same DSM criteria. Autism 
Rating Scales were not specified due to the lack of standardization across the field. The 
autism rating scales could include any one of twelve scales available, in order to measure 
mental health symptoms, measure progress of interventions, and establish methods of 
communication (Massachusetts General Hospital, 2010). Exclusion criterion for groups 1 
and 2 included type 1 diabetes, multiple sclerosis, celiac disease, and rheumatoid 
arthritis. This project was granted approval by the Clemson University Institutional 
Review Board under exempt status.  
 All samples were received at the Clemson University Healthcare Genetics 
laboratory. Upon receipt, the tubes were logged into a sample accession database. 
Plasma and gDNA received did not have any subject identifiers and were only labeled 
with a laboratory accession number, date of receipt, and laboratory technician initials. 
Information accompanying each sample was labeled with only laboratory accession 
numbers which link it to the sample received with no subject identifiers. The 
accompanying information included ethnicity, gender, and presence/absence of autism 
spectrum disorder from medical records. The samples were analyzed upon receipt.  
Design for Zonulin Measurements 
 Research shows that intestinal permeability is present in ASD and that it is linked 
with severity of ASD (Adams et al., 2011). Intestinal permeability is defined as the 
capacity by which substances can penetrate the epithelial surfaces of the intestine 
(Montalto et al., 1997). Two theories have been developed to explain the permeation 
routes: transcellular permeation through small pores and paracellular permeation 
through channels. This dissertation research focuses on the paracellular route by which 
substances travel through the tight junctions. In order to objectively measure intestinal 
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permeability, the first aim of this project targets the product of the mechanism that 
regulates intestinal permeability by quantifying zonulin in the plasma. Plasma zonulin 
levels in individuals with ASD have not been documented in the literature. The first aim 
was developed to answer the following questions: 1) what are the levels of plasma 
zonulin levels among the ASD population in comparison to normal healthy controls? 2) 
Is there a difference in plasma zonulin levels between ASD individuals with GI symptoms 
and without GI symptoms?  
 The working hypothesis is that increased zonulin levels in plasma are directly 
and significantly associated with the presence of ASD, and higher levels of plasma 
zonulin are specifically related to GI symptoms. In order to test this hypothesis, zonulin 
levels were quantified using an enzyme-linked immunosorbent assay (ELISA) from 
MyBioSource. This assay determined zonulin levels in plasma by measuring color 
changes that result from a series of steps.  
 First, a reaction plate was coated with polyclonal anti-zonulin antibodies and 
samples were added that were mixed with biotinylated zonulin tracer. Each sample was 
run in duplicate. Free target antigens in the samples competed with the biotinylated 
zonulin to bind to antibodies on the plate. Then streptavidin-labeled peroxidase antibody 
bound to the zonulin tracer, tetramethylbenzidine was added and the enzyme activity 
was stopped, yielding a color change. Absorbance readings were analyzed at 450nm and 
540nm using a Tecan Infinite M200 absorbance plate reader.  
Design for Haptoglobin Genotyping 
 One study has determined HP2-2 phenotypes are associated with ASD in males 
(Aposhian et al., 2006). HP is a protein coding gene involved in hemoglobin binding and 
catalytic activity. Genotyping can be used to determine the type of inherited alleles which 
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are then suggested to predict phenotype. HP genotyping- although used to predict 
increased risk of type 2 diabetes, sickle cell disease, vascular diseases, and cancers- is not 
commonly tested for in individuals with ASD (Cahill et al., 2013; Haas et al., 2011; 
Mandato et al., 2012; Purushothaman et al., 2012; Santos et al., 2011; Shi et al., 2012; 
Speeckaert et al., 2011; Speeckaert et al., 2012). DNA testing was not done because no 
studies have indicated a clinically relevant use for HP genotyping in relation to ASD. 
Since zonulin is pre-haptoglobin2 and it occurs in two forms, it seems genetic testing 
would be beneficial to determine the statistical relationship of each form with ASD.  
 The objective of specific aim two targets how genetics place an individual at 
greater risk to acquire ASD. Specific aim two was developed to answer the following 
questions: 1) Do genotypes of HP significantly differ between the ASD population in 
comparison to normal healthy controls? 2) Does a specific HP genotype place one at a 
higher risk of acquiring ASD? 3) How do plasma zonulin levels and HP genotype 
uniquely contribute to ASD?  
 It was postulated that HP2-2 genotypes would be significantly more abundant in 
individuals with ASD compared to healthy controls, and would place individuals with a 
HP2-2 genotype at a higher risk of acquiring ASD. This hypothesis was tested by 
genotyping HP from gDNA using real-time polymerase chain reaction (PCR). 
Preliminary studies were conducted to develop and validate a HP assay to target three 
common genotypes of HP: HP1-1, HP1-2, and HP2-2. Primers and probes were designed 
using HP sequences AC004682 and M69197 obtained from the National Center for 
Biotechnology Information nucleotide database. The probe designs target HP1 and HP2 
using proprietary rapid probe technology courtesy of Co-Diagnostics for research 
purposes. Probes and primers were synthesized by Integrated DNA Technologies.  
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[Insert Table 4.2] 
 
The preliminary validation indicates that the HP assay is able to detect presence or 
absence of HP1, HP2, and HP1/2 genotypes with no cross reactivity using a minimum 
input of 1ng gDNA. Detection limit analysis and reproducibility was determined from 
dilutions at 200fM, 20fM, 2fM, 0.2fM, and 0.02fM of each HP synthetic control in 
duplicate reactions. The estimated reproducibility between runs for HP1 targets is 0.855, 
with a 95% confidence interval (0.474, 0.982) and for HP2 targets is .990, with a 95% 
confidence interval (0.953, 0.999). Estimating reproducibility within a run, for HP1 the 
ICC = 0.984, with a 95% confidence interval (0.889, 0.998) and for HP2 the ICC = 0 
.990, with a 95% confidence interval (0.929, 0.999). T-tests were used to analyze the 
cycle threshold values between single plex and multiplex assay using a significance value 
of p< .05. The t-tests identified no significant differences in cycle thresholds between 
single plex and multiplex assays, indicating that the plexing of primers and probes 
together does not significantly affect the cycle threshold detection.  
[Insert Figure 4.1 and Figure 4.2] 
The multiplexed HP genotyping assay was performed on a CFX96 Real-time System 
using reagents acquired from Bio-Rad Laboratories (Hercules, California). Each gDNA 
sample was run in duplicate in a 20-uL reaction containing 10uL Sso Advanced 
Universal Probes Supermix (Bio-Rad) and 1-100ng of DNA. The optimal thermal cycling 
conditions included an initial denaturation step at 95˚C for 2 minutes followed by 40 
cycles of denaturation at 95˚C for 30 seconds and annealing and extension at 59˚C for 
30 seconds. Given that the positive controls indicate a growth curve before cycle 40 and 
the negative controls indicate no growth curve, samples indicating a growth curve 
between cycles 10 and 40 will be positive for the respective haptoglobin genotype. A 
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growth curve in the FAM channel indicates HP1 allele, a growth curve only in the TET 
channel only indicates HP2 allele, and those showing growth curves for both FAM and 
TET are heterozygous for HP1/2 alleles. If the positive control shows no growth curve or 
the negative control shows a growth curve, the results are invalid and the test should be 
repeated using new controls.  
Results 
 Several forms of statistical analysis were used to interpret the data. ELISA curve 
fit was performed using CurveExpert Professional version 2.0. All other analyses were 
performed using the Statistical Package for the Social Sciences (SPSS) version 21.0 (IBM 
Corporation, Released 2012). For each analysis, the categorical variables were dummy 
coded and then all variables were examined for outliers, missing values, normal 
distribution, and homogeneity. For specific aim one, a correlation analysis was 
performed between zonulin and the three groups. The results indicate a non-significant 
low positive correlation exists between plasma zonulin concentrations and the three 
groups (r= 0.206, p= 0.275), and a non-significant low negative correlation between 
haptoglobin genotypes and the three groups (r= -0.164, p= 0.387). The same type of 
analysis was used for specific aim two to determine the relationship between zonulin 
levels and haptoglobin genotypes. Very little to no correlation was found between 
zonulin and haptoglobin genotypes (r= 0.046, p= 0.808). In this case, the null 
hypothesis is accepted that there is no relationship between zonulin and sample groups, 
there is no relationship between haptoglobin genotype and sample groups, and there is 
no relationship between zonulin levels and HP genotypes. 
 A one-way ANOVA was used to test for differences in zonulin levels between the 
groups.  The significance level of p< .05 was used for the ANOVA. The results show no 
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significant differences in the means between the three groups, F (2, 27) = 0.883, p = 
0.425. Table 4.3 shows the mean zonulin levels among groups of children with ASD, 
newborns, and healthy controls. 
[Insert Table 4.3] 
Once again the null hypothesis is accepted that there are no differences in zonulin levels 
among the three groups.    
 A binary logistic regression with a significance level of p = 0.05 was run to 
determine specific aim three. A test of the model was not statistically significant from the 
constant, indicating that zonulin is not a reliable predictor between groups with autism 
and healthy controls (chi square = 1.176, p = 0.278 with df = 1).  
 Finally, Pearson’s chi square analysis was performed to determine the 
relationships between the categorical data. Chi square tests were run between groups 
and each of the variables including HP genotype and zonulin level (dichotomously coded 
high, medium, low, very low, or zero).  Statistical significance of < .05 was used for each 
chi square test. The number of subjects within each group as a function of zonulin level is 
shown in figure 5.2.  Zonulin levels were identifiable in 20% of autism individuals (at low 
levels of 2.5450 and4.9280 ng/mL), 20% of newborns (at high levels of 75.2014 and very 
low levels of 0.2710ng/mL), and 50.0% of normal controls (at very low levels between 
0.0060-0.9981 ng/mL. The assumptions for Pearson Chi-Square were violated with 75% 
having an expected count less than 5 so the likelihood ratio values were used. The 
association between zonulin levels and the three groups were significant, X2 Likelihood 
Ratio (6, N=30) = 15.277, p = 0.018. Newborns were more likely to have high levels of 
zonulin than the other groups, autism groups were more likely to have low levels of 
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zonulin than other groups, and controls were more likely to have lower levels of zonulin 
than autism or newborn groups.  
[Insert Figure 4.3] 
 The number of subjects within each group as a function of haptoglobin genotype 
is shown in figure 4.4. Heterozygous alleles of haptoglobin were present in 100% of 
individuals with autism, 90% of newborns, and 90% of healthy controls. The other 10% 
of newborns and 10% of controls were homozygous for haptoglobin 1 alleles. The 
assumptions for Pearson Chi-Square were violated with 50% having an expected count 
less than 5 so the likelihood ratio values were used. The association between haptoglobin 
genotype and the three groups were not significant, X2 Likelihood Ratio (2, N=30) = 
1.692, p = 0.429.  
[Insert Figure 4.4] 
Discussion & Conclusion 
 Even though no statistically significant levels were reached from this study, the 
absence and low levels of zonulin in healthy controls and medium to high levels of 
zonulin in individuals with ASD and newborns suggest the possibility of clinical 
significance. The zonulin levels that were present within each sample group raise 
suspicion that clinical differences in zonulin levels exist when excess zonulin does not 
clear the system shortly after birth.  The high levels of zonulin in newborns compared to 
the low levels in controls suggest that zonulin decreases over time after birth except in 
the presence of disease. It is unclear whether increased levels of zonulin at young ages 
cause disease. These suspicions could only be objectively tested with a larger number of 
samples for each group. More research is recommended to investigate the role of 
intestinal permeability and ASD. It is evident from previous research that GI symptoms 
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are more common among individuals with ASD than normal controls (Adams et al., 
2011; Buie et al., 2010). One of the major factors influencing the outcome of this 
dissertation research project was the small sample size and limited funds. With more 
funding, a larger sample size could be obtained lending itself to a better statistical 
outcome. Other potential limiting factors include reversal mechanisms of the gut which 
function to create a barrier to potential pathogens, tissue specificity of zonulin, or 
unknown variables that are not accounted for in this study (Fasano, 2011). Reversal of 
zonulin in gut function has been documented in cases of celiac disease (Drago et al., 
2006). Studies suggest that intestinal permeability increases and then returns to baseline 
over time, but the baseline levels between disease – ASD included- and normal controls 
remain significantly different (Drago et al., 2006; Tripathi et al., 2009). Since ASD 
studies documenting dietary interventions of diet indicate a plateau effect, this reversal 
mechanism has a potential to interfere with direct linear relationships between zonulin 
and ASD (Whiteley et al., 2010).  
 A study by Aposhian et al. (2006) indicates a connection between HP2-2 
genotypes and ASD, and preliminary data from social media suggests relationships exist 
between GI symptoms and ASD. However, in this study there was no significant 
differentiation in HP genotype among the three groups. Differences related to ethnicity 
were unachievable due to the availability of samples. The results from this study 
contrasted greatly from previous findings by other researchers, in that a majority of 
samples from this study are heterozygous for HP. The differences in HP genotype related 
to ASD may be the result of gender or the presence of gastrointestinal symptoms. The 
results related to ethnicity from this study are inconclusive due to small numbers of 
ethnic groups. A larger study would need to be repeated to provide better statistical 
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evidence of using HP genotype to predict risk of ASD and to define the role that ethnicity 
plays in HP genotyping and disease. For example, future studies might include more 
than just HP genotype but other genotypes associated with ASD and/or zonulin.  
 Finally, the unknown always presents a possible problem in research but it can 
only be dealt with upon discovery. In this case, zonulin has not been found to be a useful 
predictor of ASD, but the results are of significant interest in directing future research. 
Other mechanisms in the zonulin pathway may also be of interest using genome wide 
association or methylation studies among ASD. The ground work has been established 
that intestinal permeability is present in ASD and that GI symptoms are linked to 
severity, but there may be unknown factors that account for these relationships that are 
not currently known. For this reason, it is suggested that the study be replicated with 
increased sample numbers to detect zonulin levels within subgroups of ASD specific only 
to GI disorders or other potential mechanisms that are shared between intestinal 
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Haptoglobin Primer & Probe Design 
 













HP1 Probe 63.3  [FAM] atggtcctgaaagcccagaggtcgaaggacca [DABCYL]  




Dependent Variable:   zonulin   
Group ID Mean Std. 
Deviation 
N 
Autism 0.7523 1.6786 10 
Controls 0.2122 0.3274 10 
Newborn 7.5472 23.7714 10 






Table 4.1 Diseases Associated with Zonulin. A literature review search in PubMed  
acquired in August, 2013 identified the systems and diseases associated with zonulin.  
 
Table 4.2 Haptoglobin primer and probe design. The design illustrates the proprietary 
hybridization probe design based on Co-Diagnostic’s rapid probe technology. The 
fluorophores were selected to use in a complimentary fashion for multiplexing capability. 
 
Table 4.3 Descriptive Statistics. This chart shows the mean zonulin levels among the 






 Real-time PCR of HP1 Dilution Series 
  
















Figure 4.1 Real-time PCR of HP1 Dilution Series. The plot shows the cycle thresholds and 
growth curves for a HP1 control serial dilution  at 200fM, 20fM, 2fM, 0.2fM, and .02fM 
concentrations.  
 
Figure 4.2 Real-time PCR  of HP2 Dilution Series. The plot shows the cycle thresholds 
and growth curves for a HP2 control serial dilution at 200fM, 20fM, 2fM, 0.2fM, and 
.02fM concentrations.  
Figure 4.3 Effect of Zonulin on Group Identification. The graph shows the zonulin levels 
among the number of subjects within each group. 
Figure 4.4 Effect of Haptoglobin Genotype on Group Identification. The graph shows the 
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Translational research brings knowledge from multiple disciplines together and sets that 
knowledge into action within clinical practice. Using the knowledge to action framework, this 
project has moved through multiple phases from translation to research. As this research clearly 
indicates, this translational process is littered with much trial and error moving continuously from 
the translation phase back to the research phase. It almost seems as if research and translation is a 
continuous cycle with only an occasional, random institutionalization output. None-the-less, 
without continuous research as demonstrated through the previous four chapters lives would not 
be saved from disease and healthcare would not progress. Chapter I summarized how the research 
within this project fits within the knowledge to action framework. The chapter provided 
conclusions from each experiment and future directions to push forward toward 
institutionalization. 
 In chapter I, the knowledge to action framework was introduced along with brief 
summaries of how each of the subsequent research chapters would fit within the framework. This 
chapter defined translation as the process by which an application is moved from the development 
phase into action within the clinical setting. It introduced Chapter II, an article that reviews the 
current status of zonulin associated intestinal permeability and ASD and indicates a gap in early 
diagnostic testing that can be developed for clinical use. 
 Chapter III explored social media for themes and patterns of autism and GI symptoms 
collected using Radian6. It was anticipated that the themes presented first hand by individuals 
with autism, care takers, and friends or family through social media can implicate relationships 
and themes of disease that stimulate the need for further research. Three major themes were 
identified: 1) proposed links to autism, 2) symptoms related to food allergies and GI 
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issues, and 3) interventions. The pathways of disease present through social may be 
further analyzed to create pathway models for ASD and other diseases. Additionally, the 
information obtained through social media data may be used to create novel interventions. In this 
case, it is projected that preliminary exploration of ASD symptoms reported in social media 
indicate large numbers of GI dysfunction, GI symptoms, early onset of bacterial infection and 
food allergies. The research extended this investigation to look at quantitative relationships 
between ASD, HP genotypes, and quantitative zonulin levels.  
Although ELISA testing has been used as a “gold standard” method of testing for many 
diseases, this research suggested that molecular testing may prove to be a more sensitive, specific, 
and rapid way of testing for disease at an earlier stage. Real-time PCR testing can detect the 
presence of virus at early onset even before symptoms develop. The results from zonulin and 
haptoglobin testing for ASD showed no significant relationship between zonulin levels, 
haptoglobin genotype, and the presence of ASD. However, the presence of GI symptoms and the 
extremely high zonulin (>40ng/mL) in 10% of ASD and presence of zonulin at 2-5ng/mL in 
newborns compared to no zonulin detection in healthy controls suggest more research is needed. 
A larger sample population combined with more medical history and genome sequencing may 
provide answers needed to explain the mechanisms of zonulin and etiology of ASD. The 
qualitative social media data mining of ASD and GI symptoms using Radian6 supported the need 
for more genetic testing, specifically related to epigenetic and pharmacogenetic testing. The 
qualitative data indicated that genetic testing could lead toward more personalized treatment 
options whether or not it could be used for early diagnosis.  
The need to reduce trial and error that occurs during the treatment process was a repeated 
theme throughout each chapter under no boundaries of disease type. In each case, genetic testing 
and a comprehensive patient history were the common factors with the ability to reduce trial and 
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error while maintaining quality of life. Of interest was the ability of qualitative data mining of 
social media to come to such conclusion regarding genetic testing and the ability to suggest a 
model of disease pathology that may be tested experimentally. A follow up study using the 
qualitative data would be to create a pathway model designed to use data collected from social 
media to model any disease pathway. All research suggests the need for a comprehensive family 
history and log of symptoms and reactions to obtain an early diagnosis. Like many diseases, ASD 
show patterns of early onset symptoms that may or may not be readily visible to the human eye. 
Therefore, effective early diagnostic testing is desirable to detect the presence of disease or 
specific symptoms with accompanying recommendations for treatment. Pharmacogenetic testing 
presents a viable option for diseases that do not currently have a confirmatory diagnostic test in 
that it can help determine treatment options based on the body’s capacity to metabolize specific 
substances. Conclusively early diagnostic testing is desirable as long as the cost for such testing is 
minimal.  
Testing for zonulin presents a new innovative method of detecting intestinal permeability. 
To date all of the tests associating intestinal permeability with ASD have been measured using 
LM tests (De Magistris et al., 2010; D’Eufemia et al., 1996). The LM test involves oral 
administration of a solution of mannitol and lactulose with subsequent assessment of small 
intestine absorption measured by a six hour urine collection (Cooper, 1984). For children, LM 
testing has been used to determine allergies and intestinal permeability, but the methods of oral 
administration and collection are very difficult to obtain due to the use of diapers and inability of 
children to anticipate the need for urination and bowel movements. Although this research 
detected no significant relationship between zonulin levels and ASD, it does not discount the use 
of zonulin ELISA tests as a replacement for LM testing. The research here presents the use of 
zonulin ELISA testing and HP genotyping as novel early diagnostic method for intestinal 
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permeability. The implementation of these methodologies represents a paradigm shift in the use 
of proteomic and genomic diagnostic testing from clinical diagnosis to pre-symptomatic testing. 
Early diagnostic testing may prevent or reduce altered developmental endpoints and may 
specifically define the severity of the related disease. Next steps in the development of early 
diagnostic testing would be to conduct experiments to compare the use of serum zonulin testing 
to LM testing to identify which is most effective and to understand their application on a global 
scale. It may also be of interest to incorporate this testing of diagnostic techniques with the 
current autism rating scales and treatment regimens to monitor adverse events. It is inevitable for 
testing methods to remain in a cycle of research and translation. Genetic recombination events 
and mutations do not stop with time they continue to produce new phenotypes; therefore, all 
testing standards, even “gold standards,” need to be constantly re-evaluated to ensure they 
perform at optimal efficiencies. Finally, early diagnostic tests simply measured from blood 
collection could result in a rapid turn-around-time for reporting clinical results, future 
development of point-of-care assays, and provide direction and significance for continuing 
zonulin research.  
An extension of zonulin research in relation to ASD is warranted by the differences in the 
zonulin concentrations between ASD individuals (M= 0.7523, SD = 1.6786), newborns (M= 
7.5472, SD = 23.7714), and healthy controls (M= 0.2122, SD = 0.3274). With a larger samples 
size, it is possible that zonulin levels between groups will be significant. Future studies suggest 
repeating this exact experiment with at least 30 samples per group and extending the research to 
explore differences between ASD individuals with and without GI symptoms. Another aspect is 
to further explore zonulin levels from birth to adulthood to see how the levels may fluctuate 
related to changes in diet from nursing or formula to solid foods, and to study levels of zonulin 
from birth to adulthood in relation to disease development. Of additional interest would be 
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development of symptoms or disease over time in relation to the zonulin levels. Genome wide 
sequencing of all of these individuals may also help understand gene interactions related to 
intestinal permeability and patterns of inheritance. In addition to exploring zonulin levels, 
pharmacogenetics and epigenetics of ASD should be explored. 
The array of symptoms and levels of severity related to ASD make it hard for a single 
intervention to work for all individuals. Pharmacogenetics and epigenetic studies of ASD provide 
opportunities to understand metabolism and methylation patterns. Based on results from social 
media, pharmacogenetic testing should focus on medications related to pain, neurological 
conditions, and gastrointestinal symptoms. The use of pharmacogenetic testing would make 
personalization of treatment an option to avoid adverse events and frustration experienced as a 
result of trial and error interventions.  
In conclusion, future research will have translational importance in the development of 
novel early diagnostic testing for the prevention and aggressive treatment of disease. The 
development of diagnostic methodologies will lead to interventions that will improve quality of 


























APPENDIX A: GLOSSARY OF TERMS 
TERM DEFINITION REFERENCE 
Research Phase The first phase within the knowledge to action 
framework that includes discovery, efficacy, 
effectiveness, and research supporting structures. 
Wilson et al., 2011 
Translation 
Phase 
The second phase within the knowledge to action 
framework that includes translation, decisions to 
translate, knowledge into products, dissemination, 
engagement, decisions to adopt, practice, and 
translation supporting structures. 
Wilson et al., 2011 
Translation The process of putting research into clinical practice, 
which is not dependent on a certain method of 
implementation or intervention. 
Wilson et al., 2011 
Early 
Diagnostics 
A method that indicates presence/absence, risk, or 
severity of a disease or condition prior to the 
manifestation of symptoms or outside of the 




































































































































APPENDIX C: PERMISSIONS FOR USE 
1. Permission to use Figure Figure 1.1 NCCDPHP Knowledge to Action Framework for 
Public Health: 
Rebecca Garcia <ragarci@g.clemson.edu> 
Fri, Mar 7, 2014 at 9:14 
AM 
To: kwilson@cdc.gov 
Cc: Julia Eggert <jaegger@clemson.edu> 
Hi, 
 
I am writing to request permission to use the diagram of the knowledge to action framework as 
printed in:  
Wilson KM, Brady TJ, Lesesne C, on behalf of the NCCDPHP Work Group on Translation. An organizing 
framework for translation in public health: the Knowledge to Action Framework. Prev Chronic Dis 
2011;8(2):A46. http://www.cdc.gov/pcd/issues/2011/mar/10_0012.htm. 
I am using the framework as a basis for my dissertation research and would like to use the figure to 
help explain the framework. Please note that I have cc'd my advisor on this email. Thank you for your 
time and consideration. 
Thanks, 
Rebecca Garcia 
Healthcare Genetics Program 
Clemson University 
-- [The information transmitted is intended only for the person or entity to which it is addressed and may contain proprietary, 
business-confidential and/or privileged material. If you are not the intended recipient of this message you are hereby notified that any 
use, review, retransmission, dissemination, distribution, reproduction or any action taken in reliance upon this message is prohibited. If 
you received this in error, please contact the sender and delete the material from any computer.] 
 
Wilson, Katherine (Kathi) (CDC/OPHSS/CSELS) <kxw1@cdc.gov> 
Fri, Mar 7, 2014 at 12:14 
PM 
To: "ragarci@g.clemson.edu" <ragarci@g.clemson.edu> 
Cc: "jaegger@clemson.edu" <jaegger@clemson.edu> 




Of course you can use it. The journal, Preventing Chronic Disease, and I are both federal, 
which means we are in the public domain. I would appreciate you referencing the paper, 
though.  
 
Good luck. If you are so inclined to share, let me know how you used the K2A. A lot of good 
people were involved in developing it and would be glad to hear about it.  
 




2. Permission to use Figure 4.1 Bacteria and Virus Alteration of Tight Junctions: 
Rebecca Garcia <ragarci@g.clemson.edu> Fri, Jun 20, 2014 at 10:50 PM 
To: jguttman@sfu.ca 
Hi, 
I am writing to request permission to use Fig 2 from your published article "Tight junctions as targets 
of infectious agents" in Biochim Biophys Acta. 2009 Apr;1788(4):832-41. doi: 
10.1016/j.bbamem.2008.10.028. Epub 2008 Nov 14. I would like to incorporate the figure as an 
illustration in my dissertation manuscript. I appreciate your time and consideration.  
Best Regards, 
Rebecca Garcia, PhD(c) 
Healthcare Genetics Doctoral Program 
Clemson University 
-- [The information transmitted is intended only for the person or entity to which it is addressed and may contain proprietary, 
business-confidential and/or privileged material. If you are not the intended recipient of this message you are hereby notified that any 
use, review, retransmission, dissemination, distribution, reproduction or any action taken in reliance upon this message is prohibited. If 
you received this in error, please contact the sender and delete the material from any computer.] 
 
 
Julian Guttman <jguttman@sfu.ca> 
Sat, Jun 21, 2014 at 9:31 AM 




Yes, I absolutely give you permission! 
Good luck on your dissertation. 
Julian Guttman 
[Quoted text hidden] 
****************** 
Julian A. Guttman, PhD. 
Associate Professor 
CIHR New Investigator 
Department of Biological Sciences Graduate Program Chair 
  
Simon Fraser University 
8888 University Drive 
Department of Biological Sciences 
Room B8276 
Burnaby, BC V5A1S6 
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distribution, copying or other use by anyone else is strictly prohibited. If you have received this e-mail in error, 
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